Novel molecules of the card-related protein family and uses thereof

ABSTRACT

Novel CARD-3, CARD-4L and CARD-4S polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, CARD-3, CARD-4L and CARD-4S proteins, and the invention further provides isolated CARD-3, CARD-4L and CARD-4S fusion proteins, antigenic peptides and anti-CARD-3, anti-CARD-4L and anti-CARD-4S antibodies. The invention also provides CARD-3, CARD-4L and CARD-4S nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-3, CARD-4L or CARD-4S gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

[0001] CROSS REFERENCE TO RELATED APPLICATIONS

[0002] This application is a continuation-in-part of U.S. application Ser. No. 09/019,942, filed Feb. 6, 1998.

BACKGROUND OF THE INVENTION

[0003] In multicellular organisms, homeostasis is maintained by balancing the rate of cell proliferation against the rate of cell death. Cell proliferation is influenced by numerous growth factors and the expression of proto-oncogenes, which typically encourage progression through the cell cycle. In contrast, numerous events, including the expression of tumor suppressor genes, can lead to an arrest of cellular proliferation.

[0004] In differentiated cells, a particular type of cell death called apoptosis occurs when an internal suicide program is activated. This program can be initiated by a variety of external signals as well as signals that are generated within the cell in response to, for example, genetic damage. For many years, the magnitude of apoptotic cell death was not appreciated because the dying cells are quickly eliminated by phagocytes, without an inflammatory response.

[0005] The mechanisms that mediate apoptosis have been intensively studied. These mechanisms involve the activation of endogenous proteases, loss of mitochondrial function, and structural changes such as disruption of the cytoskeleton, cell shrinkage, membrane blebbing, and nuclear condensation due to degradation of DNA. The various signals that trigger apoptosis are thought to bring about these events by converging on a common cell death pathway that is regulated by the expression of genes that are highly conserved from worms, such as C. elegans, to humans. In fact, invertebrate model systems have been invaluable tools in identifying and characterizing the genes that control apoptosis. Through the study of invertebrates and more evolved animals, numerous genes that are associated with cell death have been identified, but the way in which their products interact to execute the apoptotic program is poorly understood.

[0006] Caspases, a class of proteins central to the apoptotic program, are cysteine protease having specificity for aspartate at the substrate cleavage site. These proteases are primarily responsible for the degradation of cellular proteins that lead to the morphological changes seen in cells undergoing apoptosis. For example, one of the caspases identified in humans was previously known as the interleukin-1β (IL-1β) converting enzyme (ICE), a cysteine protease responsible for the processing of pro-IL-1β to the active cytokine. Overexpression of ICE in Rat-1 fibroblasts induces apoptosis (Miura et al., Cell 75:653 [1993]).

[0007] Many caspases and proteins that interact with caspases possess domains of about 60 amino acids called a caspase recruitment domain (CARD). Hofmann et al. (TIBS 22:155 [1997]) and others have postulated that certain apoptotic proteins bind to each other via their CARDs and that different subtypes of CARDs may confer binding specificity, regulating the activity of various caspases, for example.

[0008] The functional significance of CARDs have been demonstrated in recent publications. Duan et al. (Nature 385:86 [1997]) showed that deleting the CARD at the N-terminus of RAIDD, a newly identified protein involved in apoptosis, abolished the ability of RAIDD to bind to caspases. In addition, Li et al. (Cell 91:479 [1997]) showed that the N-terminal 97 amino acids of apoptotic protease activating factor-1 (Apaf-1) was sufficient to confer caspase-9-binding ability. Inohara et al. (J. Biol. Chem. 273:12296-12300, 1998) showed that Apaf-1 can bind several other caspases such as caspase-4 and caspase-8. Apaf-1 can interact with caspases via CARD-CARD interaction (Li et al., supra, Hu et al., PNAS, 95:4386-4391, 1998).

SUMMARY OF THE INVENTION

[0009] The present invention is based, at least in part, on the discovery of genes encoding CARD-3 and CARD-4. The CARD-4 gene can express a long transcript that encodes CARD-4L or a short transcript that encodes partial CARD-4S. CARD-3 and CARD-4L/S are intracellular proteins that are predicted to be involved in regulating caspase activation.

[0010] The CARD-3 cDNA described below (SEQ ID NO:1) has a 1620 open reading frame (nucleotides 214 to 1833 of SEQ ID NO:1; SEQ ID NO:3) which encodes a 540 amino acid protein (SEQ ID NO:2). CARD-3 contains a kinase domain which extends from amino acid 1 to amino acid 300 of SEQ ID NO:2; SEQ ID NO:4, followed by a linker domain at amino acid 301 to amino acid 431 of SEQ ID NO:2; SEQ ID NO:5 and a CARD at amino acid 432 to amino acid 540 of SEQ ID NO:2; SEQ ID NO:6.

[0011] Two forms of CARD-4 exist in the cell, a long form, CARD-4L, and a short form, CARD-4S. The cDNA of CARD-4L described below (SEQ ID NO:7) has a 2859 nucleotide open reading frame (nucleotides 245-3103 of SEQ ID NO:7; SEQ ID NO:9) which encodes a 953 amino acid protein (SEQ ID NO:8). CARD-4L protein possesses a CARD domain (amino acids 15-114; SEQ ID NO:10). CARD-4L is also predicted to have a nucleotide binding domain which extends from about amino acid 198 to about amino acid 397 of SEQ ID NO:8; SEQ ID NO:11, a Walker Box “A”, which extends from about amino acid 202 to about amino acid 209 of SEQ ID NO:8; SEQ ID NO:12, a Walker Box “B”, which extends from about amino acid 280 to about amino acid 284, of SEQ ID NO:8; SEQ ID NO:13, a kinase 3a subdomain, which extends from about amino acid 327 to about amino acid 338 of SEQ ID NO:8; SEQ ID NO:14, and ten Leucine-rich repeats which extend from about amino acid 674 to about amino acid 950 of SEQ ID NO:8. The first Leucine-rich repeat extends from about amino acid 674 to about amino acid 701 of SEQ ID NO:8; SEQ ID NO:15. The second Leucine-rich repeat extends from about amino acid 702 to about amino acid 727 of SEQ ID NO:8; SEQ ID NO:16. The third Leucine-rich repeat extends from about amino acid 728 to about amino acid 754 of SEQ ID NO:8; SEQ ID NO:17. The fourth Leucine-rich repeat extends from about amino acid 755 to about amino acid 782 of SEQ ID NO:8; SEQ ID NO:18. The fifth Leucine-rich repeat extends from about amino acid 783 to about amino acid 810 of SEQ ID NO:8; SEQ ID NO:19. The sixth Leucine-rich repeat extends from about amino acid 811 to about amino acid 838 of SEQ ID NO:8; SEQ ID NO:20. The seventh Leucine-rich repeat extends from about amino acid 839 to about amino acid 866 of SEQ ID NO:8; SEQ ID NO:21. The eighth Leucine-rich repeat extends from about amino acid 867 to about amino acid 894 of SEQ ID NO:8; SEQ ID NO:22. The ninth Leucine-rich repeat extends from about amino acid 895 to about amino acid 922 of SEQ ID NO:8; SEQ ID NO:23 and the tenth leucine-rich repeat extends from about amino acid 923 to about amino acid 950 of SEQ ID NO:8; SEQ ID NO:24.

[0012] The partial cDNA of CARD-4S described below (SEQ ID NO:25) has a 1470 nucleotide open reading frame (nucleotides 1-1470 of SEQ ID NO:25; SEQ ID NO:27) which encodes a 490 amino acid protein (SEQ ID NO:26). CARD-4S protein possesses a CARD domain (amino acids 1-74 of SEQ ID NO:26; SEQ ID NO:28). CARD-4S is predicted to have a P-Loop which extends from about amino acid 163 to about amino acid 170 of SEQ ID NO:26; SEQ ID NO:29, and a Walker Box “B” which extends form about amino acid 241 to about amino acid 245 of SEQ ID NO:26; SEQ ID NO:30.

[0013] Like other proteins containing a CARD domain, both CARD-3 and CARD-4L/S are expected to participate in the network of interactions that lead to caspase activity. Human CARD-4L is expected to play a functional role in caspase activation similar to that of Apaf-1 (Zou et al., Cell, 90:405-413, 1997). For example, upon acitivation, CARD-4L might bind a nucleotide, thus allowing CARD-4L to bind and activate a CARD-containing caspase via a CARD-CARD interaction, leading to apoptotic death of the cell. Accordingly, CARD-3 and CARD-4 molecules are useful as modulating agents in regulating a variety of cellular processes including cell growth and cell death. In one aspect, this invention provides isolated nucleic acid molecules encoding CARD-3 or CARD-4 proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of CARD-3 or CARD-4 encoding nucleic acids.

[0014] The invention encompasses methods of diagnosing and treating patients who are suffering from a disorder associated with an abnormal level or rate (undesirably high or undesirably low) of apoptotic cell death, abnormal activity of the Fas/APO-1 receptor complex, abnormal activity of the TNF receptor complex, or abnormal activity of a caspase by administering a compound that modulates the expression of CARD-3 or CARD-4L/S (at the DNA, mRNA or protein level, e.g., by altering mRNA splicing) or by altering the activity of CARD-3 or CARD-4L/S. Examples of such compounds include small molecules, antisense nucleic acid molecules, ribozymes, and polypeptides.

[0015] Certain disorders are associated with an increased number of surviving cells, which are produced and continue to survive or proliferate when apoptosis is inhibited. These disorders include cancer (particularly follicular lymphomas, carcinomas associated with mutations in p53, and hormone-dependent tumors such as breast cancer, prostate cancer, and ovarian cancer), autoimmune disorders (such as systemic lupus erythematosis, immune-mediated glomerulonephritis), and viral infections (such as those caused by herpesviruses, poxviruses, and adenoviruses).

[0016] Failure to remove autoimmune cells that arise during development or that develop as a result of somatic mutation during an immune response can result in autoimmune disease. One of the molecules that plays a critical role in regulating cell death in lymphocytes is the cell surface receptor for Fas.

[0017] Populations of cells are often depleted in the event of viral infection, with perhaps the most dramatic example being the cell depletion caused by the human immunodeficiency virus (HIV). Surprisingly, most T cells that die during HIV infections do not appear to be infected with HIV. Although a number of explanations have been proposed, recent evidence suggests that stimulation of the CD4 receptor results in the enhanced susceptibility of uninfected T cells to undergo apoptosis.

[0018] A wide variety of neurological diseases are characterized by the gradual loss of specific sets of neurons. Such disorders include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) retinitis pigmentosa, spinal muscular atrophy, and various forms of cerebellar degeneration. The cell loss in these diseases does not induce an inflammatory response, and apoptosis appears to be the mechanism of cell death.

[0019] In addition, a number of hematologic diseases are associated with a decreased production of blood cells. These disorders include anemia associated with chronic disease, aplastic anemia, chronic neutropenia, and the myelodysplastic syndromes. Disorders of blood cell production, such as myelodysplastic syndrome and some forms of aplastic anemia, are associated with increased apoptotic cell death within the bone marrow. These disorders could result from the activation of genes that promote apoptosis, acquired deficiencies in stromal cells or hematopoietic survival factors, or the direct effects of toxins and mediators of immune responses.

[0020] Two common disorders associated with cell death are myocardial infarctions and stroke. In both disorders, cells within the central area of ischemia, which is produced in the event of acute loss of blood flow, appear to die rapidly as a result of necrosis. However, outside the central ischemic zone, cells die over a more protracted time period and morphologically appear to die by apoptosis.

[0021] The invention features a nucleic acid molecule which is at least 45% (or 55%, 65%, 75%, 85%, 95%, or 98%) identical to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID:25, SEQ ID NO:27, the nucleotide sequence of the cDNA insert of the plasmid deposited with ATCC as Accession Number (the “cDNA of ATCC ______”), the nucleotide sequence of the cDNA insert of the plasmid deposited with ATCC as Accession Number (the “cDNA of ATCC ______”), the nucleotide sequence of the cDNA insert of the plasmid deposited with ATCC as Accession Number (the “cDNA of ATCC ______”), or a complement thereof.

[0022] The invention features a nucleic acid molecule which includes a fragment of at least 150 (300, 325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1300, 1600 or 1931) nucleotides of the nucleotide sequence shown in SEQ ID NO:1, or SEQ ID NO:3, or the nucleotide sequence of the cDNA ATCC ______, or a complement thereof.

[0023] The invention also features a nucleic acid molecule which includes a fragment of at least 150 (350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1300, 1600, 1900, 2100, 2400, 2700, 3000, or 3382) nucleotides of the nucleotide sequence shown in SEQ ID NO:7, or SEQ ID NO:9, or the nucleotide sequence of the cDNA ATCC , or a complement thereof.

[0024] Also within the invention is a nucleic acid molecule which includes a fragment of at least 150 (350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1300, 1600, 1900, 2100, 2400, 2700, and 3080) nucleotides of the nucleotide sequence shown in SEQ ID NO:25, or SEQ ID NO:27, or the nucleotide sequence of the cDNA ATCC , or a complement thereof.

[0025] The invention features a nucleic acid molecule which includes a nucleotide sequence encoding a protein having an amino acid sequence that is at least 45% (or 55%, 65%, 75%, 85%, 95%, or 98%) identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO: 26 or the amino acid sequence encoded by the cDNA of ATCC ______, the amino acid sequence encoded by the cDNA of ATCC ______, or the amino acid sequence encoded by the cDNA of ATCC ______.

[0026] In a preferred embodiment, a CARD-3 nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO:1, or SEQ ID NO:3, or the nucleotide sequence of the cDNA of ATCC ______. In another preferred embodiment, a CARD-4L nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO:7, or SEQ ID NO:9, or the nucleotide sequence of the cDNA of ATCC ______. In yet another preferred embodiment, a CARD-4S nucleic acid molecule has the nucleotide sequence shown in SEQ ID NO:25, or SEQ ID NO:27, or the nucleotide sequence of the cDNA of ATCC ______.

[0027] Also within the invention is a nucleic acid molecule which encodes a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26, the fragment including at least 15 (25, 30, 50, 100, 150, 300, 400 or 540, 600, 700, 800, 953) contiguous amino acids of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26 or the polypeptide encoded by the cDNA of ATCC Accession Number ______, or the polypeptide encoded by the cDNA of ATCC Accession Number ______, or the polypeptide encoded by the cDNA of ATCC Accession Number ______.

[0028] The invention includes a nucleic acid molecule which encodes a naturally occuring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or an amino acid sequence encoded by the cDNA of ATCC Accession Number ______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions. The invention also includes a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA of ATCC Accession Number______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 or SEQ ID NO:9 under stringent conditions.

[0029] The invention also includes a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA of ATCC Accession Number ______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:25 or SEQ ID NO:27 under stringent conditions.

[0030] Also within the invention are: an isolated CARD-3 protein having an amino acid sequence that is at least about 65%, preferably 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:2; an isolated CARD-3 protein having an amino acid sequence that is at least about 85%, 95%, or 98% identical to the kinase domain of SEQ ID NO:2 (e.g., about amino acid residues 1 to 300 of SEQ ID NO:2; SEQ ID NO:4); and an isolated CARD-3 protein having an amino acid sequence that is at least about 85%, 95%, or 98% identical to the linker domain of SEQ ID NO:2 (e.g., about amino acid residues 301 to 431 of SEQ ID NO:2; SEQ ID NO:5); an isolated CARD-3 protein having an amino acid sequence that is at least about 85%, 95%, or 98% identical to the CARD domain of SEQ ID NO:2 (e.g., about amino acid residues 432 to 540 of SEQ ID NO:2; SEQ ID NO:6); an isolated CARD-4L protein having an amino acid sequence that is at least about 65%, preferably 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:8; an isolated CARD-4L protein having an amino acid sequence that is at least about 85%, 95%, or 98% identical to the CARD domain of SEQ ID NO:8 (e.g., about amino acid residues 15 to 114 of SEQ ID NO:8; SEQ ID NO:10); an isolated CARD-4L protein having an amino acid sequence that is at least about 85%, 95%, or 98% identical to the nucleotide binding domain of SEQ ID NO:8 (e.g., about amino acid residues 198 to 397 of SEQ ID NO:8; SEQ ID NO:11; an isolated CARD-4L protein having an amino acid sequence that is at least about 85%, 95%, or 98% identical to a kinase 3a subdomain of SEQ ID NO:8 (e.g., about amino acid residues 327 to 338 of SEQ ID NO:8; SEQ ID NO:14); an isolated CARD-4L protein having an amino acid sequence that is at least about 85%, 95%, or 98% identical to the Leucine-rich repeats of SEQ ID NO:8 (e.g., about amino acid residues 674 to 701 of SEQ ID NO:8; SEQ ID NO:15; from amino acid 702 to amino acid 727 of SEQ ID NO:8; SEQ ID NO:16; which extends from amino acid 728 to amino acid 754 SEQ ID NO:8; SEQ ID NO:17; from amino acid 755 to amino acid 782 of SEQ ID NO:8; SEQ ID NO:18; from amino acid 783 to amino acid 810 of SEQ ID NO:8; SEQ ID NO:19; from amino acid 811 to amino acid 838 of SEQ ID NO:8; SEQ ID NO:20 from amino acid 839 to amino acid 866 of SEQ ID NO:8; SEQ ID NO:21; from amino acid 867 to amino acid 894 of SEQ ID NO:8; SEQ ID NO:22; from amino acid 895 to amino acid 922 of SEQ ID NO:8; SEQ ID NO:23; and from amino acid 923 to amino acid 950 of SEQ ID NO:8; SEQ ID NO:24); an isolated CARD-4S protein having an amino acid sequence that is at least about 65%, preferably 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:26; an isolated CARD-4S protein having an amino acid sequence that is at least about 85%, 95%, or 98% identical to the CARD domain of SEQ ID NO:26 (e.g., about amino acid residues 1 to 74 of SEQ ID NO:26; SEQ ID NO:28).

[0031] Also within the invention are: an isolated CARD-3 protein which is encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 65%, preferably 75%, 85%, or 95% identical to SEQ ID NO:3 or the cDNA of ATCC ______; an isolated CARD-3 protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical to the kinase domain encoding portion of SEQ ID NO:1 (e.g., about nucleotides 213 to 1113 of SEQ ID NO:1); an isolated CARD-3 protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical the linker domain encoding portion of SEQ ID NO:1 (e.g., about nucleotides 1114 to 1506 of SEQ ID NO:1); and an isolated CARD-3 protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical the CARD domain encoding portion of SEQ ID NO:1 (e.g., about nucleotides 1507 to 1833 of SEQ ID NO:1); and an isolated CARD-3 protein which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:3 or the non-coding strand of the cDNA of ATCC ______.

[0032] Also within the invention are: an isolated CARD-4L protein which is encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 65%, preferably 75%, 85%, or 95% identical to SEQ ID NO:9 or the cDNA of ATCC ______; an isolated CARD-4L protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical the CARD domain encoding portion of SEQ ID NO:7 (e.g., about nucleotides 287 to 586 o SEQ ID NO:7); an isolated CARD-4L protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical the nucleotide binding domain encoding portion of SEQ ID NO:7 (e.g., about nucleotides 836 to 1436 of SEQ ID NO:7); an isolated CARD-4L protein which is encoded by a nucleic acid molecule having a kinase 3a subdomain at least about 65% preferably 75%, 85%, or 95% identical the nucleotide binding domain encoding portion of SEQ ID NO:7 (e.g., about nucleotides 1223 to 1258 of SEQ ID NO:7); an isolated CARD-4L protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical the Leucine-rich repeats encoding portion of SEQ ID NO:7 (e.g., about nucleotides 2264 to 2347 of SEQ ID NO:7; about nucleotides 2348 to 2425 of SEQ ID NO:7; about nucleotides 2426 to 2506 of SEQ ID NO:7; about nucleotides 2507 to 2590 of SEQ ID NO:7; about nucleotides 2591 to 2674 of SEQ ID NO:7; about nucleotides 2675 to 2758 of SEQ ID NO:7; about nucleotides 2759 to 2842 of SEQ ID NO:7; about nucleotides 2843 to 2926 of SEQ ID NO:7; about nucleotides 2927 to 3010 of SEQ ID NO:7; about nucleotides 3011 to 3094 of SEQ ID NO:7; and an isolated CARD-4L protein which is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:9 or the non-coding strand of the cDNA of ATCC ______.

[0033] Also within the invention are: an isolated CARD-4S protein which is encoded by a nucleic acid molecule having a nucleotide sequence that is at least about 65%, preferably 75%, 85%, or 95% identical to SEQ ID NO:27 or the cDNA of ATCC ______; an isolated CARD-3 protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical the CARD domain encoding portion of SEQ ID NO:25 (e.g., about nucleotides 1 to 222 of SEQ ID NO:25); an isolated CARD-3 protein which is encoded by a nucleic acid molecule having a nucleotide sequence at least about 65% preferably 75%, 85%, or 95% identical the P-Loop encoding portion of SEQ ID NO:25 (e.g., about nucleotides 485 to 510 of SEQ ID NO:25).

[0034] Also within the invention is a polypeptide which is a naturally occurring allelic variant of a polypeptide that includes the amino acid sequence of SEQ ID NO:2 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or SEQ ID NO:3 under stringent conditions.

[0035] Also within the invention is a polypeptide which is a naturally occurring allelic variant of a polypeptide that includes the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 or SEQ ID NO:9 under stringent conditions.

[0036] Also within the invention is a polypeptide which is a naturally occurring allelic variant of a polypeptide that includes the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:25 or SEQ ID NO:27 under stringent conditions.

[0037] Another embodiment of the invention features CARD-3 or CARD-4L/S nucleic acid molecules which specifically detect CARD-3 or CARD-4L/S nucleic acid molecules, relative to nucleic acid molecules encoding other members of the CARD superfamily. For example, in one embodiment, a CARD-4L nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:7, SEQ ID NO:9, or the cDNA of ATCC ______, or a complement thereof. In another embodiment, the CARD-4L nucleic acid molecule is at least 300 (350, 400, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1300, 1600, 1900, 2100, 2400, 2700, 3000, or 3382) nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:7, SEQ ID NO:9, the cDNA of ATCC ______, or a complement thereof. In another embodiment, an isolated CARD-4L nucleic acid molecule comprises nucleotides 287 to 586 of SEQ ID NO:7, encoding the CARD domain of CARD-4L, or a complement thereof. In yet another embodiment, the invention provides an isolated nucleic acid molecule which is antisense to the coding strand of a CARD-4L nucleic acid.

[0038] Another aspect of the invention provides a vector, e.g., a recombinant expression vector, comprising a CARD-3 or a CARD-4L/S nucleic acid molecule of the invention. In another embodiment the invention provides a host cell containing such a vector. The invention also provides a method for producing CARD-3 or CARD-4L/S protein by culturing, in a suitable medium, a host cell of the invention containing a recombinant expression vector such that a CARD-3 or CARD-4L/S protein is produced.

[0039] Another aspect of this invention features isolated or recombinant CARD-3 or CARD-4L/S proteins and polypeptides. Preferred CARD-3 or CARD-4L/S proteins and polypeptides possess at least one biological activity possessed by naturally occurring human CARD-3 or CARD-4L/S, e.g., (1) the ability to form protein:protein interactions with proteins in the apoptotic signalling pathway; (2) the ability to form CARD-CARD interactions with proteins in the apoptotic signaling pathway, (3) the ability to bind the CARD-3 or CARD-4L/S ligand; (4) the ability to bind to an intracellular target; and (5) the ability to bind to caspases. Other activities include: (1) modulation of cellular proliferation, (2) modulation of cellular differentiation and (3) modulation of cellular death.

[0040] The CARD-3 or CARD-4L/S proteins of the present invention, or biologically active portions thereof, can be operatively linked to a non-CARD-3 or non-CARD-4L/S polypeptide (e.g., heterologous amino acid sequences) to form CARD-3 or CARD-4L/S fusion proteins, respectively. The invention further features antibodies that specifically bind CARD-3 or CARD-4L/S proteins, such as monoclonal or polyclonal antibodies. In addition, the CARD-3 or CARD-4L/S proteins or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers.

[0041] In another aspect, the present invention provides a method for detecting the presence of CARD-3 or CARD-4L/S activity or expression in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of CARD-3 or CARD-4L/S activity such that the presence of CARD-3 or CARD-4L/S activity is detected in the biological sample.

[0042] In another aspect, the invention provides a method for modulating CARD-3 or CARD-4L/S activity comprising contacting a cell with an agent that modulates (inhibits or stimulates) CARD-3 or CARD-4L/S activity or expression such that CARD-3 or CARD-4L/S activity or expression in the cell is modulated. In one embodiment, the agent is an antibody that specifically binds to CARD-3 or CARD-4L/S protein. In another embodiment, the agent modulates expression of CARD-3 or CARD-4L/S by modulating transcription of a CARD-3 or CARD-4L/S gene, splicing of a CARD-3 or CARD-4L/S mRNA, or translation of a CARD-3 or CARD-4L/S mRNA. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of the CARD-3 or CARD-4L/S mRNA or the CARD-3 or CARD-4L/S gene.

[0043] In one embodiment, the methods of the present invention are used to treat a subject having a disorder characterized by aberrant CARD-3 or CARD-4L/S protein or nucleic acid expression or activity by administering an agent which is a CARD-3 or CARD-4L/S modulator to the subject. In one embodiment, the CARD-3 or CARD-4L/S modulator is a CARD-3 or CARD-4L/S protein. In another embodiment the CARD-3 or CARD-4L/S modulator is a CARD-3 or CARD-4L/S nucleic acid molecule. In other embodiments, the CARD-3 or CARD-4L/S modulator is a peptide, peptidomimetic, or other small molecule.

[0044] The present invention also provides a diagnostic assay for identifying the presence or absence of a genetic lesion or mutation characterized by at least one of: (i) aberrant modification or mutation of a gene encoding a CARD-3 or CARD-4L/S protein; (ii) mis-regulation of a gene encoding a CARD-3 or CARD-4L/S protein; and (iii) aberrant post-translational modification of a CARD-3 or CARD-4L/S protein, wherein a wild-type form of the gene encodes a protein with a CARD-3 or CARD-4L/S activity.

[0045] In another aspect, the invention provides a method for identifying a compound that binds to or modulates the activity of a CARD-3 or CARD-4L/S protein. In general, such methods entail measuring a biological activity of a CARD-3 or CARD-4L/S protein in the presence and absence of a test compound and identifying those compounds which alter the activity of the CARD-3 or CARD-4L/S protein.

[0046] The invention also features methods for identifying a compound which modulates the expression of CARD-3 or CARD-4L/S by measuring the expression of CARD-3 or CARD-4L/S in the presence and absence of a compound.

[0047] Other features and advantages of the invention will be apparent from the following detailed description and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

[0048]FIG. 1 depicts the cDNA sequence (SEQ ID NO:1) of human CARD-3. The open reading frame of CARD-3 (SEQ ID NO:1) extends from nucleotide 213 to nucleotide 1833 nucleotide (SEQ ID NO:3).

[0049]FIG. 2 depicts the predicted amino acid sequence (SEQ ID NO:2) of human CARD-3.

[0050]FIG. 3 depicts the cDNA sequence (SEQ ID NO:7) of CARD-4L. The open reading frame of SEQ ID NO:7 extends from nucleotide 245 to nucleotide 3103 (SEQ ID NO:9).

[0051]FIG. 4 depicts the predicted amino acid sequence (SEQ ID NO:8) of human CARD-4L.

[0052]FIG. 5 depicts the partial cDNA sequence (SEQ ID NO:25) of CARD-4S and the predicted amino acid sequence (SEQ ID NO:25) of human CARD-4S. The open reading frame of CARD-4 (SEQ ID NO:25) extends from nucleotide 1 to nucleotide 1470 (SEQ ID NO:27).

[0053]FIG. 6 depicts the predicted amino acid sequence (SEQ ID NO:26) of human CARD-4S.

[0054]FIG. 7 depicts an alignment of the CARD domains of CARD-4 (SEQ ID NO:10), CARD-3 (SEQ ID NO:6), ARC-CARD (SEQ ID NO:31), cIAP1-CARD (SEQ ID NO:32), cIAP1-CARD (SEQ ID NO:33) and cIAP2-CARD (SEQ ID NO:34).

[0055]FIG. 8 is a plot showing predicted structural features of human CARD-4L.

[0056]FIG. 9 is a plot showing predicted structural features of human CARD-4S.

DETAILED DESCRIPTION OF THE INVENTION

[0057] The present invention is based on the discovery of a cDNA molecule encoding human CARD-3 and human CARD-4 proteins. A nucleotide sequence encoding a human CARD-3 protein is shown in FIG. 1 (SEQ ID NO:1; SEQ ID NO:3 includes the open reading frame only). A predicted amino acid sequence of CARD-3 protein is also shown in FIG. 2 (SEQ ID NO: 2). CARD-4 has two forms, a long form, CARD-4L, and a short form, CARD-4S. A nucleotide sequence encoding a human CARD-4L protein is shown in FIG. 3 (SEQ ID NO:7; SEQ ID NO:9 includes the open reading frame only). A predicted amino acid sequence of CARD-4L protein is also shown in FIG. 4 (SEQ ID NO:8). A nucleotide sequence encoding a partial human CARD-4S protein is shown in FIG. 5 (SEQ ID NO:25; SEQ ID NO:27 includes the open reading frame only). A predicted amino acid sequence of CARD-4S protein is also shown in FIG. 6 (SEQ ID NO:26).

[0058] The human CARD-3 cDNA of FIG. 1 (SEQ ID NO:1), which is approximately 1931 nucleotides long including untranslated regions, encodes a protein amino acid having a molecular weight of approximately 61 kDa (excluding post-translational modifications). A plasmid containing a cDNA encoding human CARD-3 (with the cDNA insert name of ______) was deposited with American Type Culture Collection (ATCC), Rockville, Maryland ______ on and assigned Accession Number ______. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

[0059] The human CARD-4L cDNA of FIG. 3 (SEQ ID NO:7), which is approximately 3382 nucleotides long including untranslated regions, encodes a protein amino acid having a molecular weight of approximately 108 kDa (excluding post-translational modifications). A plasmid containing a cDNA encoding human CARD-4L (with the cDNA insert name of ) was deposited with American Type Culture Collection (ATCC), Rockville, Md. on ______ and assigned Accession Number ______. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

[0060] The human partial CARD-4S cDNA of FIG. 5 (SEQ ID NO:25), which is approximately 3080 nucleotides long including untranslated regions. A plasmid containing a cDNA encoding human CARD-4S (with the cDNA insert name of ) was deposited with American Type Culture Collection (ATCC), Rockville, Md. on ______ and assigned Accession Number ______. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure. This deposit was made merely as a convenience for those of skill in the art and is not an admission that a deposit is required under 35 U.S.C. §112.

[0061] A region of human CARD-4L protein (SEQ ID NO:8) bears some similarity to a CARD domain of CARD-3 (SEQ ID NO:6), ARC-CARD (SEQ ID NO:31), cIAP1-CARD (SEQ ID NO:32), cIAP1-CARD (SEQ ID NO:33) and cIAP2-CARD (SEQ ID NO:34). This comparison is depicted in FIG. 7.

[0062] Human CARD-3 or CARD-4L/S are members of a family of molecules (the “CARD family”) having certain conserved structural and functional features. The term “family” when referring to the protein and nucleic acid molecules of the invention is intended to mean two or more proteins or nucleic acid molecules having a common structural domain and having sufficient amino acid or nucleotide sequence identity as defined herein. Such family members can be naturally occurring and can be from either the same or different species. For example, a family can contain a first protein of human origin and a homologue of that protein of murine origin, as well as a second, distinct protein of human origin and a murine homologue of that protein. Members of a family may also have common functional characteristics.

[0063] In one embodiment, a CARD-3 or CARD-4L or CARD-4S protein includes a CARD domain having at least about 65%, preferably at least about 75%, and more preferably about 85%, 95%, or 98% amino acid sequence identity to the CARD domain of SEQ ID NO:6 or the CARD domain of SEQ ID NO:10 or the CARD domain of SEQ ID NO:28.

[0064] Preferred CARD-3 or CARD-4L or CARD-4S polypeptides of the present invention have an amino acid sequence sufficiently identical to the CARD domain consensus amino acid sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:28, respectively. The CARD-3 polypeptide also has an amino acid sequence sufficiently identical to the kinase domain consensus sequence of SEQ ID NO:4, and an amino acid sequence that is sufficiently identical to the linker domain of SEQ ID NO:5. The CARD-4L polypeptide has an amino acid sequence sufficiently identical to the nucleotide binding domain of SEQ ID NO:11, an amino acid sequence sufficiently identical to the Walker Box “A” of SEQ ID NO:12 or Walker Box “B” of SEQ ID NO:13, or an amino acid sequence sufficiently identical to the kinase 3a subdomain of SEQ ID NO:14, or an amino acid sequence sufficiently identical to the Leucine-rich repeats of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO: 19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO: 22, and SEQ ID NO: 23. As used herein, the term “sufficiently identical” refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., an amino acid residue which has a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity. For example, amino acid or nucleotide sequences which contain a common structural domain having about 65% identity, preferably 75% identity, more preferably 85%, 95%, or 98% identity are defined herein as sufficiently identical.

[0065] As used interchangeably herein a “CARD-3 or CARD-4L/S activity”, “biological activity of CARD-3 or CARD-4L/S” or “functional activity of CARD-3 or CARD-4L/S”, refers to an activity exerted by a CARD-3 or CARD-4L/S protein, polypeptide or nucleic acid molecule on a CARD-3 or CARD-4L/S responsive cell as determined in vivo, or in vitro, according to standard techniques. A CARD-3 or CARD-4L/S activity can be a direct activity, such as an association with or an enzymatic activity on a second protein or an indirect activity, such as a cellular signaling activity mediated by interaction of the CARD-3 or CARD-4L/S protein with a second protein. In a preferred embodiment, a CARD-3 or CARD-4L/S activity includes at least one or more of the following activities: (i) interaction with proteins in the apoptotic signalling pathway (ii) interaction with a CARD-3 or CARD-4L/S ligand; or (iii) interaction with an intracellular target protein; (iv) interaction with caspases.

[0066] Accordingly, another embodiment of the invention features isolated CARD-3 or CARD-4L/S proteins and polypeptides having a CARD-3 or CARD-4L/S activity.

[0067] Various aspects of the invention are described in further detail in the following subsections.

[0068] I. Isolated Nucleic Acid Molecules

[0069] One aspect of the invention pertains to isolated nucleic acid molecules that encode CARD-3 or CARD-4L/S proteins or biologically active portions thereof, as well as nucleic acid molecules sufficient for use as hybridization probes to identify CARD-3 or CARD-4L/S-encoding nucleic acids (e.g., CARD-3 or CARD-4L/S mRNA) and fragments for use as PCR primers for the amplification or mutation of CARD-3 or CARD-4L/S nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

[0070] An “isolated” nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences (preferably protein encoding sequences) which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated CARD-3 or CARD-4L/S nucleic acid molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

[0071] A nucleic acid molecule of the present invention, e.g., a nuc having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 25, SEQ ID NO: 26, the cDNA of ATCC ______, the cDNA of ATCC ______, or the cDNA of ATCC ______, or a complement of any of these nucleotide sequences, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 25, SEQ ID NO: 26, the cDNA of ATCC ______, the cDNA of ATCC ______, or the cDNA of ATCC ______ as a hybridization probe, CARD-3 or CARD-4L/S nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

[0072] A nucleic acid of the invention can be amplified using cDNA, mRNA or genomic DNA as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to CARD-3 or CARD-4L/S nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

[0073] In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 25, SEQ ID NO: 26, the cDNA of ATCC ______, the cDNA of ATCC ______, the cDNA of ATCC , or a portion thereof. A nucleic acid molecule which is complementary to a given nucleotide sequence is one which is sufficiently complementary to the given nucleotide sequence that it can hybridize to the given nucleotide sequence thereby forming a stable duplex.

[0074] Moreover, the nucleic acid molecule of the invention can comprise only a portion of a nucleic acid sequence encoding CARD-3 or CARD-4L/S, for example, a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of CARD-3 or CARD-4L/S. The nucleotide sequence determined from the cloning of the human CARD-3 or CARD-4L/S gene allows for the generation of probes and primers designed for use in identifying and/or cloning CARD-3 or CARD-4L/S homologues in other cell types, e.g., from other tissues, as well as CARD-3 or CARD-4L/S homologues from other mammals. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 250, 300, 350 or 400 consecutive nucleotides of the sense or anti-sense sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, the cDNA of ATCC ______, the cDNA of ATCC ______ or of a naturally occurring mutant of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, the cDNA of ATCC ______, or the cDNA of ATCC ______.

[0075] Probes based on the human CARD-3 or CARD-4L/S nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or identical proteins. The probe comprises a label group attached thereto, e.g., a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which mis-express a CARD-3 or CARD-4L/S protein, such as by measuring a level of a CARD-3 or CARD-4L/S-encoding nucleic acid in a sample of cells from a subject, e.g., detecting CARD-3 or CARD-4L /S mRNA levels or determining whether a genomic CARD-3 or CARD-4L/S gene has been mutated or deleted.

[0076] A nucleic acid fragment encoding a “biologically active portion of CARD-3 or CARD-4L/S” can be prepared by isolating a portion of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, or the nucleotide sequence of the cDNA of ATCC ______, or the nucleotide sequence of the cDNA of ATCC ______ which encodes a polypeptide having a CARD-3 or CARD-4L/S biological activity, expressing the encoded portion of CARD-3 or CARD-4L/S protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of CARD-3 or CARD-4L/S. For example, a nucleic acid fragment encoding a biologically active portion of CARD-3 or CARD-4L/S includes a CARD domain, e.g., SEQ ID NO:6 and SEQ ID NO:10 or SEQ ID NO:26.

[0077] The invention further encompasses nucleic acid molecules that differ from the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:25, SEQ ID NO:27, the cDNA of ATCC ______, or the cDNA of ATCC ______, or the cDNA of ATCC ______ due to degeneracy of the genetic code and thus encode the same CARD-3 or CARD-4L/S protein as that encoded by the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:25, SEQ ID NO:27, the cDNA of ATCC ______, the cDNA of ATCC ______, or the cDNA of ATCC ______.

[0078] In addition to the human CARD-3 or CARD-4L/S nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:25, SEQ ID NO:27, the cDNA of ATCC ______, the cDNA of ATCC ______, or the cDNA of ATCC ______, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of CARD-3 or CARD-4L/S may exist within a population (e.g., the human population). Such genetic polymorphism in the CARD-3 or CARD-4L/S gene may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame encoding a CARD-3 or CARD-4L/S protein, preferably a mammalian CARD-3 or CARD-4L/S protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the CARD-3 or CARD-4L/S gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in CARD-3 or CARD-4L/S that are the result of natural allelic variation and that do not alter the functional activity of CARD-3 or CARD-4L/S are intended to be within the scope of the invention.

[0079] Moreover, nucleic acid molecules encoding CARD-3 or CARD-4L/S proteins from other species (CARD-3 or CARD-4L/S homologues), which have a nucleotide sequence which differs from that of a human CARD-3 or CARD-4L/S, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the CARD-3 or CARD-4L/S cDNA of the invention can be isolated based on their identity to the human CARD-3 or CARD-4L/S nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.

[0080] Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 300 (325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, 1300, 1600 or 1931) nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:1, SEQ ID NO:3, or the cDNA of ATCC ______. In yet another embodiment, an isolated nucleic acid molecule of the invention is at least 300 (325, 350, 375, 400, 425, 450, 500, 550, 600, 650, 700, 800, 900, 1000, or 1300, 1640, 1900, 2200, 2500, 2800, 3100, or 3382) nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence, preferably the coding sequence, of SEQ ID NO:7, SEQ ID NO:9, the cDNA of ATCC ______.

[0081] As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% (65%, 70%, preferably 75%) identical to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6× sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 50-65° C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO:1, SEQ ID NO:3, the cDNA of ATCC corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

[0082] In addition to naturally-occurring allelic variants of the CARD-3 or CARD-4L/S sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:25, SEQ ID NO:26, the cDNA of ATCC ______, the cDNA of ATCC ______, or the cDNA of ATCC ______, thereby leading to changes in the amino acid sequence of the encoded CARD-3 or CARD-4L/S protein, without altering the functional ability of the CARD-3 or CARD-4L/S protein. For example, one can make nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of CARD-3 or CARD-4L/S (e.g., the sequence of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26) without altering the biological activity, whereas an “essential” amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the CARD-3 or CARD-4L/S proteins of various species are predicted to be particularly unamenable to alteration.

[0083] For example, preferred CARD-3 or CARD-4L/S proteins of the present invention, contain at least one CARD domain. Additionally, a CARD-3 protein also contains at least one kinase domain or at least one linker domain. A preferred CARD domain contains at least one nucleotide binding domain or Leucine-rich repeats. Such conserved domains are less likely to be amenable to mutation. Other amino acid residues, however, (e.g., those that are not conserved or only semi-conserved among CARD-3 or CARD-4L/S of various species) may not be essential for activity and thus are likely to be amenable to alteration.

[0084] Accordingly, another aspect of the invention pertains to nucleic acid molecules encoding CARD-3 or CARD-4L/S proteins that contain changes in amino acid residues that are not essential for activity. Such CARD-3 or CARD-4L/S proteins differ in amino acid sequence from SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:25 and yet retain biological activity. In one embodiment, the isolated nucleic acid molecule includes a nucleotide sequence encoding a protein that includes an amino acid sequence that is at least about 45% identical, 65%, 75%, 85%, 95%, or 98% identical to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26.

[0085] An isolated nucleic acid molecule encoding a CARD-3 or CARD-4L/S protein having a sequence which differs from that of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26, respectively, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of CARD-3 (SEQ ID NO:1, SEQ ID NO:3, the cDNA of ATCC ______) or CARD-4L (SEQ ID NO:7, SEQ ID NO:9, the cDNA of ATCC ______), or CARD-4S (SEQ ID NO:25, SEQ ID NO:27, the cDNA of ATCC ______) such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in CARD-3 or CARD-4L/S is preferably replaced with another amino acid residue from the same side chain family. Alternatively, mutations can be introduced randomly along all or part of a CARD-3 or CARD-4L/S coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for CARD-3 or CARD-4L/S biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

[0086] In a preferred embodiment, a mutant CARD-3 or CARD-4L/S protein can be assayed for: (1) the ability to form protein:protein interactions with proteins in the apoptotic signalling pathway; (2) the ability to bind a CARD-3 or CARD-4L/S ligand; or (3) the ability to bind to an intracellular target protein. In yet another preferred embodiment, a mutant CARD-3 or CARD-4L/S can be assayed for the ability to modulate cellular proliferation, cellular differentiation, or cellular death.

[0087] The present invention encompasses antisense nucleic acid molecules, i.e., molecules which are complementary to a sense nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire CARD-3 or CARD-4L/S coding strand, or to only a portion thereof, e.g., all or part of the protein coding region (or open reading frame). An antisense nucleic acid molecule can be antisense to a noncoding region of the coding strand of a nucleotide sequence encoding CARD-3 or CARD-4L/S. The noncoding regions (“5′ and 3′ untranslated regions”) are the 5′ and 3′ sequences which flank the coding region and are not translated into amino acids.

[0088] Given the coding strand sequences encoding CARD-3 or CARD-4L/S disclosed herein (e.g., SEQ ID NO:1 or SEQ ID NO:3 or SEQ ID NO:7 or SEQ ID NO:9 or SEQ ID NO:25 or SEQ ID NO:27), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of CARD-3 or CARD-4L/S mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of CARD-3 or CARD-4L/S mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of CARD-3 mRNA, e.g., an oligonucleotide having the sequence CCCTGGTACTTGCCCCTCCGGTAG (SEQ ID NO:35) or CCTGGTACTTGCCCCTCC (SEQ ID NO:36) or of the CARD-4L mRNA e.g., TCGTTAAGCCCTTGAAGACAGTG (SEQ ID NO:37) and TCGTTAGCCCTTGAAGACCAGTGAGTGTAG (SEQ ID NO:38). An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

[0089] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a CARD-3 or CARD-4L/S protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention include direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

[0090] An antisense nucleic acid molecule of the invention can be an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gaultier et al. (1987) Nucleic Acids. Res. 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res. 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215:327-330).

[0091] The invention also encompasses ribozymes. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can be used to catalytically cleave CARD-3 or CARD-4L/S mRNA transcripts to thereby inhibit translation of CARD-3 or CARD-4L/S mRNA. A ribozyme having specificity for a CARD-3 or CARD-4L/S-encoding nucleic acid can be designed based upon the nucleotide sequence of a CARD-3 or CARD-4L/S cDNA disclosed herein (e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:25 and SEQ ID NO:27). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a CARD-3 or CARD-4L/S-encoding mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, CARD-3 or CARD-4L/S mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel and Szostak (1993) Science 261:1411-1418.

[0092] The invention also encompasses nucleic acid molecules which form triple helical structures. For example, CARD-3 or CARD-4L/S gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the CARD-3 or CARD-4L/S (e.g., the CARD-3 or CARD-4L/S promoter and/or enhancers) to form triple helical structures that prevent transcription of the CARD-3 or CARD-4L/S gene in target cells. See generally, Helene (1991) Anticancer Drug Des. 6(6):569-84; Helene (1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher (1992) Bioassays 14(12):807-15.

[0093] In preferred embodiments, the nucleic acid molecules of the invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorganic & Medicinal Chemistry 4(1): 5-23). As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93: 14670-675.

[0094] PNAs of CARD-3 or CARD-4L/S can be used therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of CARD-3 or CARD-4L/S can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup (1996) supra; or as probes or primers for DNA sequence and hybridization (Hyrup (1996) supra; Perry-O'Keefe et al. (1996) Proc. Natl. Acad. Sci. USA 93: 14670-675).

[0095] In another embodiment, PNAs of CARD-3 or CARD-4L/S can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of CARD-3 or CARD-4L/S can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNAse H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) supra and Finn et al. (1996) Nucleic Acids Research 24(17):3357-63. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)amino-5′-deoxy-thymidine phosphoramidite, can be used as a between the PNA and the 5′ end of DNA (Mag et al. (1989) Nucleic Acid Res. 17:5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment (Finn et al. (1996) Nucleic Acids Research 24(17):3357-63). Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment (Peterser et al. (1975) Bioorganic Med. Chem. Lett. 5:1119-11124).

[0096] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al. (1989) Proc. Natl. Acad. Sci. USA 86:6553-6556; Lemaitre et al. (1987) Proc. Natl. Acad. Sci. USA 84:648-652; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol et al. (1988) Bio/Techniques 6:958-976) or intercalating agents (see, e.g., Zon (1988) Pharm. Res. 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

[0097] II. Isolated CARD-3 or CARD-4L/S Proteins and Anti-CARD-3 or CARD-4L/S Antibodies

[0098] One aspect of the invention pertains to isolated CARD-3 or CARD-4L/S proteins, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-CARD-3 or CARD-4L/S antibodies. In one embodiment, native CARD-3 or CARD-4L/S proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, CARD-3 or CARD-4L/S proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a CARD-3 or CARD-4L/S protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

[0099] An “isolated” or “purified” protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the CARD-3 or CARD-4L/S protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of CARD-3 or CARD-4L/S protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, CARD-3 or CARD-4L/S protein that is substantially free of cellular material includes preparations of CARD-3 or CARD-4L/S protein having less than about 30%, 20%, 10%, or 5% (by dry weight) of non-CARD-3 or CARD-4L/S protein (also referred to herein as a “contaminating protein”). When the CARD-3 or CARD-4L/S protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When CARD-3 or CARD-4L/S protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly such preparations of CARD-3 or CARD-4L/S protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or non-CARD-3 or CARD-4L/S chemicals.

[0100] Biologically active portions of a CARD-3 or CARD-4L/S protein include peptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the CARD-3 or CARD-4L/S protein (e.g., the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26), which include less amino acids than the full length CARD-3 or CARD-4L/S proteins, and exhibit at least one activity of a CARD-3 or CARD-4L/S protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the CARD-3 or CARD-4L/S protein. A biologically active portion of a CARD-3 or CARD-4L/S protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Preferred biologically active polypeptides include one or more identified CARD-3 or CARD-4L/S structural domains, e.g., the CARD domain (SEQ ID NO:6 or SEQ ID NO:10 or SEQ ID NO:27).

[0101] Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native CARD-3 or CARD-4L/S protein.

[0102] Preferred CARD-3 or CARD-4L/S protein has the amino acid sequence shown of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26, respectively. Other useful CARD-3 or CARD-4L/S proteins are substantially identical to SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26, respectively, and retain the functional activity of the protein of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26, yet differ in amino acid sequence due to natural allelic variation or mutagenesis. CARD-3 and CARD-4L/S may be involved in activating caspases in the apoptotic pathway. Accordingly, a useful CARD-3 or CARD-4L/S protein is a protein which includes an amino acid sequence at least about 45%, preferably 55%, 65%, 75%, 85%, 95%, or 99% identical -to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26 and retains the functional activity of the CARD-3 or CARD-4L/S proteins of SEQ ID NO:2 or SEQ ID NO:8 or SEQ ID NO:26. In other instances, the CARD-3 or CARD-4L/S protein is a protein having an amino acid sequence 55%, 65%, 75%, 85%, 95%, or 98% identical to the CARD-3 or CARD-4L CARD domain (SEQ ID NO:6, SEQ ID NO:10 and SEQ ID NO:27). In a preferred embodiment, the CARD-3 or CARD-4L/S protein retains a functional activity of the CARD-3 or CARD-4L/S protein of SEQ ID NO:2, SEQ ID NO:8 or SEQ ID NO:26.

[0103] To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=# of identical positions/total # of positions ×100).

[0104] The determination of percent homology between two sequences can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) Proc. Nat'l Acad. Sci. USA 87:2264-2268, modified as in Karlin and Altschul (1993) Proc. Nat'l Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, et al. (1990) J. Mol. Biol. 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to CARD-3 or CARD-4L/S nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to CARD-3 or CARD-4L/S protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See http://www.ncbi.nlm.nih.gov. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

[0105] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

[0106] The invention also provides CARD-3 or CARD-4L/S chimeric or fusion proteins. As used herein, a CARD-3 or CARD-4L/S “chimeric protein” or “fusion protein” comprises a CARD-3 or CARD-4L/S polypeptide operatively linked to a non-CARD-3 or CARD-4L/S polypeptide. A “CARD-3 or CARD-4L/S polypeptide” refers to a polypeptide having an amino acid sequence corresponding to CARD-3 or CARD-4L/S, whereas a “non-CARD-3 or CARD-4L/S polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially identical to the CARD-3 or CARD-4L/S protein, e.g., a protein which is different from the CARD-3 or CARD-4L/S protein and which is derived from the same or a different organism. Within a CARD-3 or CARD-4L/S fusion protein the CARD-3 or CARD-4L/S polypeptide can correspond to all or a portion of a CARD-3 or CARD-4L/S protein, preferably at least one biologically active portion of a CARD-3 or CARD-4L/S protein. Within the fusion protein, the term “operatively linked” is intended to indicate that the CARD-3 or CARD-4L/S polypeptide and the non-CARD-3 or non-CARD-4L/S polypeptide are fused in-frame to each other. The non-CARD-3 or non-CARD-4L/S polypeptide can be fused to the N-terminus or C-terminus of the CARD-3 or CARD-4L/S polypeptide.

[0107] One useful fusion protein is a GST-CARD-3 or GST-CARD-4L/S fusion protein in which the CARD-3 or CARD-4L/S sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant CARD-3 or CARD-4L/S.

[0108] In another embodiment, the fusion protein contains a signal sequence from another protein. In certain host cells (e.g., mammalian host cells), expression and/or secretion of CARD-3 or CARD-4L/S can be increased through use of a heterologous signal sequence. For example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, Calif.). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Molecular cloning, Sambrook et al, second edition, Cold spring harbor laboratory press, 1989) and the protein A secretory signal (Pharmacia Biotech; Piscataway, N.J.).

[0109] In yet another embodiment, the fusion protein is an CARD-3 or CARD-4L/S-immunoglobulin fusion protein in which all or part of CARD-3 or CARD-4L/S is fused to sequences derived from a member of the immunoglobulin protein family. The CARD-3 or CARD-4L/S-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a CARD-3 or CARD-4L/S ligand and a CARD-3 or CARD-4L/S protein on the surface of a cell, to thereby suppress CARD-3 or CARD-4L/S-mediated signal transduction in vivo. The CARD-3 or CARD-4L/S-immunoglobulin fusion proteins can be used to affect the bioavailability of a CARD-3 or CARD-4L/S cognate ligand. Inhibition of the CARD-3 ligand/CARD-3 or CARD-4L/S ligand/CARD-4L/S interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g. promoting or inhibiting) cell survival. Moreover, the CARD-3 or CARD-4L/S-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-CARD-3 or CARD-4L/S antibodies in a subject, to purify CARD-3 or CARD-4L/S ligands and in screening assays to identify molecules which inhibit the interaction of CARD-3 or CARD-4L/S with a CARD-3 or CARD-4L/S ligand.

[0110] Preferably, a CARD-3 or CARD-4L/S chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Current Protocols in Molecular Biology, Ausubel et al. eds., John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). An CARD-3 or CARD-4L/S-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the CARD-3 or CARD-4L/S protein.

[0111] The present invention also pertains to variants of the CARD-3 or CARD-4L/S proteins which function as either CARD-3 or CARD-4L/S agonists (mimetics) or as CARD-3 or CARD-4L/S antagonists. Variants of the CARD-3 or CARD-4L/S protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the CARD-3 or CARD-4L/S protein. An agonist of the CARD-3 or CARD-4L/S protein can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of the CARD-3 or CARD-4L/S protein. An antagonist of the CARD-3 or CARD-4L/S protein can inhibit one or more of the activities of the naturally occurring form of the CARD-3 or CARD-4L/S protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the CARD-3 or CARD-4L/S protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. Treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein can have fewer side effects in a subject relative to treatment with the naturally occurring form of the CARD-3 or CARD-4L/S proteins.

[0112] Variants of the CARD-3 or CARD-4L/S protein which function as either CARD-3 or CARD-4L/S agonists (mimetics) or as CARD-3 or CARD-4L/S antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants of the CARD-3 or CARD-4L/S protein for CARD-3 or CARD-4L/S protein agonist or antagonist activity. In one embodiment, a variegated library of CARD-3 or CARD-4L/S variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of CARD-3 or CARD-4L/S variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential CARD-3 or CARD-4L/S sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of CARD-3 or CARD-4L/S sequences therein. There are a variety of methods which can be used to produce libraries of potential CARD-3 or CARD-4L/S variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential CARD-3 or CARD-4L/S sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).

[0113] In addition, libraries of fragments of the CARD-3 or CARD-4L/S protein coding sequence can be used to generate a variegated population of CARD-3 or CARD-4L/S fragments for screening and subsequent selection of variants of a CARD-3 or CARD-4L/S protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a CARD-3 or CARD-4L/S coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the CARD-3 or CARD-4L/S protein.

[0114] Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of CARD-3 or CARD-4L/S proteins. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify CARD-3 or CARD-4L/S variants (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3) :327-331).

[0115] An isolated CARD-3 or CARD-4L/S protein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind CARD-3 or CARD-4L/S using standard techniques for polyclonal and monoclonal antibody preparation. The full-length CARD-3 or CARD-4L/S protein can be used or, alternatively, the invention provides antigenic peptide fragments of CARD-3 or CARD-4L/S for use as immunogens. The antigenic peptide of CARD-3 or CARD-4L/S comprises at least 8 (preferably 10, 15, 20, or 30) amino acid residues of the amino acid sequence shown in SEQ ID NO:2, SEQ ID NO:8 or SEQ ID NO:26, and encompasses an epitope of CARD-3 or CARD-4L/S such that an antibody raised against the peptide forms a specific immune complex with CARD-3 or CARD-4L/S.

[0116] Preferred epitopes encompassed by the antigenic peptide are regions of CARD-3 or CARD-4L/S that are located on the surface of the protein, e.g., hydrophilic regions. Other important criteria include a preference for a terminal sequence, high antigenic index (e.g., as predicted by Jameson-Wolf algorithm), ease of peptide synthesis (e.g., avoidance of prolines); and high surface probability (e.g., as predicted by the Emini algorithm; FIG. 8 and FIG. 9).

[0117] A CARD-3 or CARD-4L/S immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed CARD-3 or CARD-4L/S protein or a chemically synthesized CARD-3 or CARD-4L/S polypeptide. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic CARD-3 or CARD-4L/S preparation induces a polyclonal anti-CARD-3 or CARD-4L/S antibody response.

[0118] Accordingly, another aspect of the invention pertains to anti-CARD-3 or CARD-4L/S antibodies. The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds an antigen, such as CARD-3 or CARD-4L/S. A molecule which specifically binds to CARD-3 or CARD-4L/S is a molecule which binds CARD-3 or CARD-4L/S, but does not substantially bind other molecules in a sample, e.g., a biological sample, which naturally contains CARD-3 or CARD-4L/S. Examples of immunologically active portions of immunoglobulin molecules include F(ab) and F(ab′)₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The invention provides polyclonal and monoclonal antibodies that bind CARD-3 or CARD-4L/S. The term “monoclonal antibody” or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope of CARD-3 or CARD-4L/S. A monoclonal antibody composition thus typically displays a single binding affinity for a particular CARD-3 or CARD-4L/S protein with which it immunoreacts.

[0119] Polyclonal anti-CARD-3 or CARD-4L/S antibodies can be prepared as described above by immunizing a suitable subject with a CARD-3 or CARD-4L/S immunogen. The anti-CARD-3 or CARD-4L/S antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized CARD-3 or CARD-4L/S. If desired, the antibody molecules directed against CARD-3 or CARD-4L/S can be isolated from the mammal (e.g., from the blood) and further purified by well-known techniques, such as protein A chromatography to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-CARD-3 or CARD-4L/S antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique originally described by Kohler and Milstein (1975) Nature 256:495-497, the human B cell hybridoma technique (Kozbor et al. (1983) Immunol Today 4:72), the EBV-hybridoma technique (Cole et al. (1985), Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) or trioma techniques. The technology for producing various antibodies monoclonal antibody hybridomas is well known (see generally Current Protocols in Immunology (1994) Coligan et al. (eds.) John Wiley & Sons, Inc., New York, N.Y.). Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a CARD-3 or CARD-4L/S immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds CARD-3 or CARD-4L/S.

[0120] Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-CARD-3 or CARD-4L/S monoclonal antibody (see, e.g., Current Protocols in Immunology, supra; Galfre et al. (1977) Nature 266:55052; R. H. Kenneth, in Monoclonal Antibodies: A New Dimension In Biological Analyses, Plenum Publishing Corp., New York, N.Y. (1980); and Lerner (1981) Yale J. Biol. Med., 54:387-402. Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line, e.g., a myeloma cell line that is sensitive to culture medium containing hypoxanthine, aminopterin and thymidine (“HAT medium”). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp2/O-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol (“PEG”). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind CARD-3 or CARD-4L/S, e.g., using a standard ELISA assay.

[0121] Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-CARD-3 or CARD-4L/S antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with CARD-3 or CARD-4L/S to thereby isolate immunoglobulin library members that bind CARD-3 or CARD-4L/S. Kits for generating and screening phage display libraries are commercially available (e.g., the Pharmacia Recombinant Phage Antibody System, Catalog No. 27-9400-01; and the Stratagene SurfZAP™ Phage Display Kit, Catalog No. 240612). Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Pat. No. 5,223,409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) Bio/Technology 9:1370-1372; Hay et al. (1992) Hum. Antibod. Hybridomas 3:81-85; Huse et al. (1989) Science 246:1275-1281; Griffiths et al. (1993) EMBO J 12:725-734.

[0122] Additionally, recombinant anti-CARD-3 or CARD-4L/S antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example using methods described in PCT Publication No. WO 87/02671; European Patent Application 184,187; European Patent Application 171,496; European Patent Application 173,494; PCT Publication No. WO 86/01533; U.S. Pat. No. 4,816,567; European Patent Application 125,023; Better et al. (1988) Science 240:1041-1043; Liu et al. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443; Liu et al. (1987) J. Immunol. 139:3521-3526; Sun et al. (1987) Proc. Natl. Acad. Sci. USA 84:214-218; Nishimura et al. (1987) Canc. Res. 47:999-1005; Wood et al. (1985) Nature 314:446-449; and Shaw et al. (1988) J. Natl. Cancer Inst. 80:1553-1559); Morrison, (1985) Science 229:1202-1207; Oi et al. (1986) Bio/Techniques 4:214; U.S. Pat. 5,225,539; Jones et al. (1986) Nature 321:552-525; Verhoeyan et al. (1988) Science 239:1534; and Beidler et al. (1988) J. Immunol. 141:4053-4060.

[0123] An anti-CARD-3 or CARD-4L/S antibody (e.g., monoclonal antibody) can be used to isolate CARD-3 or CARD-4L/S by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-CARD-3 or CARD-4L/S antibody can facilitate the purification of natural CARD-3 or CARD-4L/S from cells and of recombinantly produced CARD-3 or CARD-4L/S expressed in host cells. Moreover, an anti-CARD-3 or CARD-4L/S antibody can be used to detect CARD-3 or CARD-4L/S protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the CARD-3 or CARD-4L/S protein. Anti-CARD-3 or CARD-4L/S antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹¹³I, ¹³⁵S or ³H.

[0124] III. Recombinant Expression Vectors and Host Cells

[0125] Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding CARD-3 or CARD-4L/S (or a portion thereof). As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors, expression vectors, are capable of directing the expression of genes to which they are operatively linked. In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids (vectors). However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

[0126] The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell). The term “regulatory sequence” is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., CARD-3 or CARD-4L/S proteins, mutant forms of CARD-3 or CARD-4L/S, fusion proteins, etc.).

[0127] The recombinant expression vectors of the invention can be designed for expression of CARD-3 or CARD-4L/S in prokaryotic or eukaryotic cells, e.g., bacterial cells such as E. coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0128] Expression of proteins in prokaryotes is most often carried out in E. coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson (1988) Gene 67:31-40), PMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

[0129] Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., (1988) Gene 69:301-315) and pET lid (Studier et al., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV5 promoter.

[0130] One strategy to maximize recombinant protein expression in E. coli is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in E. coli (Wada et al. (1992) Nucleic Acids Res. 20:2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

[0131] In another embodiment, the CARD-3 or CARD-4L/S expression vector is a yeast expression vector. Examples of vectors for expression in yeast S. cerivisae include pYepSec1 (Baldari et al. (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz, (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54:113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picz (InVitrogen Corp, San Diego, Calif.).

[0132] Alternatively, CARD-3 or CARD-4L/S can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al. (1983) Mol. Cell Biol. 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).

[0133] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of Sambrook et al. (supra).

[0134] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert et al. (1987) Genes Dev. 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) Adv. Immunol. 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) EMBO J. 8:729-733) and immunoglobulins (Banerji et al. (1983) Cell 33:729-740; Queen and Baltimore (1983) Cell 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) Proc. Natl. Acad. Sci. USA 86:5473-5477), pancreas-specific promoters (Edlund et al. (1985) Science 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) Science 249:374-379) and the α-fetoprotein promoter (Campes and Tilghman (1989) Genes Dev. 3:537-546).

[0135] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to CARD-3 or CARD-4L/S mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub et al. (Reviews—Trends in Genetics, Vol. 1(1) 1986).

[0136] Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

[0137] A host cell can be any prokaryotic or eukaryotic cell. For example, CARD-3 or CARD-4L/S protein can be expressed in bacterial cells such as E. coli, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

[0138] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (supra), and other laboratory manuals.

[0139] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding CARD-3 or CARD-4L/S or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

[0140] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce a (i.e., express) CARD-3 or CARD-4L/S protein. Accordingly, the invention further provides methods for producing CARD-3 or CARD-4L/S protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding CARD-3 or CARD-4L/S has been introduced) in a suitable medium such that CARD-3 or CARD-4L/S protein is produced. In another embodiment, the method further comprises isolating CARD-3 or CARD-4L/S from the medium or the host cell.

[0141] The host cells of the invention can also be used to produce nonhuman transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which CARD-3 or CARD-4L/S-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous CARD-3 or CARD-4L/S sequences have been introduced into their genome or homologous recombinant animals in which endogenous CARD-3 or CARD-4L/S sequences have been altered. Such animals are useful for studying the function and/or activity of CARD-3 or CARD-4L/S and for identifying and/or evaluating modulators of CARD-3 or CARD-4L/S activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, an “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous CARD-3 or CARD-4L/S gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

[0142] A transgenic animal of the invention can be created by introducing CARD-3 or CARD-4L/S-encoding nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. The CARD-3 or CARD-4L/S cDNA sequence e.g., that of (SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:25, SEQ ID NO:27, or the cDNA of ATCC______, or the cDNA of ATCC ______, or the cDNA of ATCC) can be introduced as a transgene into the genome of a non-human animal. Alternatively, a nonhuman homologue of the human CARD-3 or CARD-4L/S gene, such as a mouse CARD-3 or CARD-4L/S gene, can be isolated based on hybridization to the human CARD-3 or CARD-4L/S cDNA and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably linked to the CARD-3 or CARD-4L/S transgene to direct expression of CARD-3 or CARD-4L/S protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, U.S. Pat. No. 4,873,191 and in Hogan, Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals.

[0143] A transgenic founder animal can be identified based upon the presence of the CARD-3 or CARD-4L/S transgene in its genome and/or expression of CARD-3 or CARD-4L/S mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene encoding CARD-3 or CARD-4L/S can further be bred to other transgenic animals carrying other transgenes.

[0144] To create an homologous recombinant animal, a vector is prepared which contains at least a portion of a CARD-3 or CARD-4L/S gene (e.g., a human or a non-human homolog of the 10 CARD-3 or CARD-4L/S gene, e.g., a murine CARD-3 or CARD-4L/S gene) into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the CARD-3 or CARD-4L/S gene. In a preferred embodiment, the vector is designed such that, upon homologous recombination, the endogenous CARD-3 or CARD-4L/S gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous CARD-3 or CARD-4L/S gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous CARD-3 or CARD-4L/S protein). In the homologous recombination vector, the altered portion of the CARD-3 or CARD-4L/S gene is flanked at its 5′ and 3′ ends by additional nucleic acid of the CARD-3 or CARD-4L/S gene to allow for homologous recombination to occur between the exogenous CARD-3 or CARD-4L/S gene carried by the vector and an endogenous CARD-3 or CARD-4L/S gene in an embryonic stem cell. The additional flanking CARD-3 or CARD-4L/S nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′ and 3′ ends) are included in the vector (see, e.g., Thomas and Capecchi (1987) Cell 51:503 for a description of homologous recombination vectors). The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced CARD-3 or CARD-4L/S gene has homologously recombined with the endogenous CARD-3 or CARD-4L/S gene are selected (see, e.g., Li et al. (1992) Cell 69:915). The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras (see, e.g., Bradley in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, Robertson, ed. (IRL, Oxford, 1987) pp. 113-152). A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley (1991) Current Opinion in Bio/Technology 2:823-829 and in PCT Publication Nos. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

[0145] In another embodiment, transgenic non-humans animals can be produced which contain selected systems which allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. (1992) Proc. Natl. Acad. Sci. USA 89:6232-6236. Another example of a recombinase system is the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

[0146] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut et al. (1997) Nature 385:810-813 and PCT Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G_(o) phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

[0147] IV. Pharmaceutical Compositions

[0148] The CARD-3 or CARD-4L/S nucleic acid molecules, CARD-3 or CARD-4L/S proteins, and anti-CARD-3 or CARD-4L/S antibodies (also referred to herein as “active compounds”) of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0149] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0150] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF; Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0151] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a CARD-3 or CARD-4L/S protein or anti-CARD-3 or CARD-4L/S antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0152] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0153] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0154] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0155] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0156] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0157] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (U.S. Pat. 5,328,470) or by stereotactic injection (see, e.g., Chen et al. (1994) Proc. Natl. Acad. Sci. USA 91:3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

[0158] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0159] V. Uses and Methods of the Invention

[0160] The nucleic acid molecules, proteins, protein homologues, and antibodies described herein can be used in one or more of the following methods: a) screening assays; b) detection assays (e.g., chromosomal mapping, tissue typing, forensic biology), c) predictive medicine (e.g., diagnostic assays, prognostic assays, monitoring clinical trials, and pharmacogenomics); and d) methods of treatment (e.g., therapeutic and prophylactic). A CARD-3 or CARD-4L/S protein interacts with other cellular proteins and can thus be used for (i) regulation of cellular proliferation; (ii) regulation of cellular differentiation; and (iii) regulation of cell survival. The isolated nucleic acid molecules of the invention can be used to express CARD-3 or CARD-4L/S protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect CARD-3 or CARD-4L/S mRNA (e.g., in a biological sample) or a genetic lesion in a CARD-3 or CARD-4L/S gene, and to modulate CARD-3 or CARD-4L/S activity. In addition, the CARD-3 or CARD-4L/S proteins can be used to screen drugs or compounds which modulate the CARD-3 or CARD-4L/S activity or expression as well as to treat disorders characterized by insufficient or excessive production of CARD-3 or CARD-4L/S protein or production of CARD-3 or CARD-4L/S protein forms which have decreased or aberrant activity compared to CARD-3 or CARD-4L/S wild type protein. In addition, the anti-CARD-3 or CARD-4L/S antibodies of the invention can be used to detect and isolate CARD-3 or CARD-4L/S proteins and modulate CARD-3 or CARD-4L/S activity.

[0161] This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

[0162] A. Screening Assays

[0163] The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) which bind to CARD-3 or CARD-4L/S proteins or have a stimulatory or inhibitory effect on, for example, CARD-3 or CARD-4L/S expression or CARD-3 or CARD-4L/S activity.

[0164] In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of a CARD-3 or CARD-4L/S protein or polypeptide or biologically active portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des. 12:145). Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422; Zuckermann et al. (1994). J. Med. Chem. 37:2678; Cho et al. (1993) Science 261:1303; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; and Gallop et al. (1994) J. Med. Chem. 37:1233.

[0165] Libraries of compounds may be presented in solution (e.g., Houghten (1992) Bio/Techniques 13:412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364:555-556), bacteria (U.S. Pat. No. 5,223,409), spores (U.S. Pat. Nos. 5,571,698; 5,403,484; and 5,223,409), plasmids (Cull et al. (1992) Proc. Natl. Acad. Sci. USA 89:1865-1869) or on phage (Scott and Smith (1990) Science 249:386-390; Devlin (1990) Science 249:404-406; Cwirla et al. (1990) Proc. Natl. Acad. Sci. 87:6378-6382; and Felici (1991) J. Mol. Biol. 222:301-310).

[0166] Determining the ability of the test compound to modulate the activity of CARD-3 or CARD-4L/S or a biologically active portion thereof can be accomplished, for example, by determining the ability of the CARD-3 or CARD-4L/S protein to bind to or interact with a CARD-3 or CARD-4L/S target molecule. As used herein, a “target molecule” is a molecule with which a CARD-3 or CARD-4L/S protein binds or interacts in nature, for example, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A CARD-3 or CARD-4L/S target molecule can be a non-CARD-3 or CARD-4L/S molecule or a CARD-3 or CARD-4L/S protein or polypeptide of the present invention. In one embodiment, a CARD-3 or CARD-4L/S target molecule is a component of a apoptotic signal transduction pathway, e.g., caspase-s. The target, for example,-can be a second intercellular protein which has catalytic activity or a protein which facilitates the association of downstream signaling molecules with CARD-3 or CARD-4L/S.

[0167] Determining the ability of the CARD-3 or CARD-4L/S protein to bind to or interact with a CARD-3 or CARD-4L/S target molecule can be accomplished by one of the methods described above for determining direct binding. In a preferred embodiment, determining the ability of the CARD-3 or CARD-4L/S protein to bind to or interact with a CARD-3 or CARD-4L/S target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (e.g., intracellular Ca²⁺, diacylglycerol, IP3, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (e.g., a CARD-3 or CARD-4L/S-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g. luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

[0168] In yet another embodiment, an assay of the present invention is a cell-free assay comprising contacting a CARD-3 or CARD-4L/S protein or biologically active portion thereof with a test compound and determining the ability of the test compound to bind to the CARD-3 or CARD-4L/S protein or biologically active portion thereof. Binding of the test compound to the CARD-3 or CARD-4L/S protein can be determined either directly or indirectly as described above. In a preferred embodiment, the assay includes contacting the CARD-3 or CARD-4L/S protein or biologically active portion thereof with a known compound which binds CARD-3 or CARD-4L/S to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a CARD-3 or CARD-4L/S protein, wherein determining the ability of the test compound to interact with a CARD-3 or CARD-4L/S protein comprises determining the ability of the test compound to preferentially bind to CARD-3 or CARD-4L/S or biologically active portion thereof as compared to the known compound.

[0169] In another embodiment, an assay is a cell-free assay comprising contacting CARD-3 or CARD-4L/S protein or biologically active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the CARD-3 or CARD-4L/S protein or biologically active portion thereof. Determining the ability of the test compound to modulate the activity of CARD-3 or CARD-4L/S can be accomplished, for example, by determining the ability of the CARD-3 or CARD-4L/S protein to bind to a CARD-3 or CARD-4L/S target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of CARD-3 or CARD-4L/S can be accomplished by determining the ability of the CARD-3 or CARD-4L/S protein further modulate a CARD-3 or CARD-4L/S target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as previously described.

[0170] In yet another embodiment, the cell-free assay comprises contacting the CARD-3 or CARD-4L/S protein or biologically active portion thereof with a known compound which binds CARD-3 or CARD-4L/S to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a CARD-3 or CARD-4L/S protein, wherein determining the ability of the test compound to interact with a CARD-3 or CARD-4L/S protein comprises determining the ability of the CARD-3 or CARD-4L/S protein to preferentially bind to or modulate the activity of a CARD-3 or CARD-4L/S target molecule. The cell-free assays of the present invention are amenable to use of both the soluble form or the membrane-associated form of CARD-3 or CARD-4L/S. A membrane-associated form of CARD-3 or CARD-4L/S refers to CARD-3 or CARD-4L/S that interacts with a membrane-bound target molecule. In the case of cell-free assays comprising the membrane-associated form of CARD-3 or CARD-4L/S, it may be desirable to utilize a solubilizing agent such that the membrane-associated form of CARD-3 or CARD-4L/S is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton® X-100, Triton® X-114, Thesit®, Isotridecypoly(ethylene glycol ether)n, 3-[(3-cholamidopropyl)dimethylamminio]-1-propane sulfonate (CHAPS), 3-[(3-cholamidopropyl)dimethylamminio]-2-hydroxy-1-propane sulfonate (CHAPSO), or N-dodecyl=N,N-dimethyl-3-ammonio-1-propane sulfonate.

[0171] In more than one embodiment of the above assay methods of the present invention, it may be desirable to immobilize either CARD-3 or CARD-4L/S or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to CARD-3 or CARD-4L/S, or interaction of CARD-3 or CARD-4L/S with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows one or both of the proteins to be bound to a matrix. For example, glutathione-S-transferase/CARD-3 or CARD-4L/S fusion proteins or glutathione-S-transferase/target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical; St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the test compound or the test compound and either the non-adsorbed target protein or CARD-3 or CARD-4L/S protein, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtitre plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described above. Alternatively, the complexes can be dissociated from the matrix, and the level of CARD-3 or CARD-4L/S binding or activity determined using standard techniques.

[0172] Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either CARD-3 or CARD-4L/S or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated CARD-3 or CARD-4L/S or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals; Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with CARD-3 or CARD-4L/S or target molecules but which do not interfere with binding of the CARD-3 or CARD-4L/S protein to its target molecule can be derivatized to the wells of the plate, and unbound target or CARD-3 or CARD-4L/S trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the CARD-3 or CARD-4L/S or target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the CARD-3 or CARD-4L/S or target molecule.

[0173] In another embodiment, modulators of CARD-3 or CARD-4L/S expression are identified in a method in which a cell is contacted with a candidate compound and the expression of CARD-3 or CARD-4L/S mRNA or protein in the cell is determined. The level of expression of CARD-3 or CARD-4L/S mRNA or protein in the presence of the candidate compound is compared to the level of expression of CARD-3 or CARD-4L/S mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of CARD-3 or CARD-4L/S expression based on this comparison. For example, when expression of CARD-3 or CARD-4L/S mRNA or protein is greater (statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of CARD-3 or CARD-4L/S mRNA or protein expression. Alternatively, when expression of CARD-3 or CARD-4L/S mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of CARD-3 or CARD-4L/S mRNA or protein expression. The level of CARD-3 or CARD-4L/S mRNA or protein expression in the cells can be determined by methods described herein for detecting CARD-3 or CARD-4L/S mRNA or protein.

[0174] In yet another aspect of the invention, the CARD-3 or CARD-4L/S proteins can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Bio/Techniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and PCT Publication No. WO 94/10300), to identify other proteins, which bind to or interact with CARD-3 or CARD-4L/S (“CARD-3 or CARD-4L/S-binding proteins” or “CARD-3 or CARD-4L/S-bp”) and modulate CARD-3 or CARD-4L/S activity. Such CARD-3 or CARD-4L/S-binding proteins are also likely to be involved in the propagation of signals by the CARD-3 or CARD-4L/S proteins as, for example, upstream or downstream elements of the CARD-3 or CARD-4L/S pathway.

[0175] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for CARD-3 or CARD-4L/S is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming an CARD-3 or CARD-4L/S-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with CARD-3 or CARD-4L/S.

[0176] This invention further pertains to novel agents identified by the above-described screening assays and uses thereof for treatments as described herein.

[0177] B. Detection Assays

[0178] Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. For example, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. These applications are described in the subsections below.

[0179] 1. Chromosome Mapping

[0180] Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. Accordingly, CARD-3 or CARD-4L/S nucleic acid molecules described herein or fragments thereof, can be used to map the location of CARD-3 or CARD-4L/S genes on a chromosome. The mapping of the CARD-3 or CARD-4L/S sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.

[0181] Briefly, CARD-3 or CARD-4L/S genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the CARD-3 or CARD-4L/S sequences. Computer analysis of CARD-3 or CARD-4L/S sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the CARD-3 or CARD-4L/S sequences will yield an amplified fragment.

[0182] Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but human cells can, the one human chromosome that contains the gene encoding the needed enzyme, will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. (D'Eustachio et al. (1983) Science 220:919-924). Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.

[0183] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the CARD-3 or CARD-4L/S sequences to design oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes. Other mapping strategies which can similarly be used to map a CARD-3 or CARD-4L/S sequence to its chromosome include in situ hybridization (described in Fan et al. (1990) Proc. Natl. Acad. Sci. USA 87:6223-27), pre-screening with labeled flow-sorted chromosomes, and pre-selection by hybridization to chromosome specific cDNA libraries.

[0184] Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step.

[0185] Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa.

[0186] A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases will suffice to get good results at a reasonable amount of time. For a review of this technique, see Verma et al., (Human Chromosomes: A Manual of Basic Techniques (Pergamon Press, New York, 1988)).

[0187] Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.

[0188] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, Mendelian Inheritance in Man, available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland et al. (1987) Nature, 325:783-787.

[0189] Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the CARD-3 or CARD-4L/S gene can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

[0190] 2. Tissue Typing

[0191] The CARD-3 or CARD-4L/S sequences of the present invention can also be used to identify individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. This method does not suffer from the current limitations of “Dog Tags” which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional DNA markers for RFLP (described in U.S. Pat. No. 5,272,057).

[0192] Furthermore, the sequences of the present invention can be used to provide an alternative technique which determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the CARD-3 or CARD-4L/S sequences described herein can be used to prepare two PCR primers from the 5′ and 3′ ends of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

[0193] Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the present invention can be used to obtain such identification sequences from individuals and from tissue. The CARD-3 or CARD-4L/S sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of SEQ ID NO:1, SEQ ID NO:7 and SEQ ID NO:25 can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers which each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in SEQ ID NO:3, SEQ ID NO:9, and SEQ ID NO:27 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

[0194] If a panel of reagents from CARD-3 or CARD-4L/S sequences described herein is used to generate a unique identification database for an individual, those same reagents can later be used to identify tissue from that individual. Using the unique identification database, positive identification of the individual, living or dead, can be made from extremely small tissue samples.

[0195] 3. Use of Partial CARD-3 or CARD-4L/S Sequences in Forensic Biology

[0196] DNA-based identification techniques can also be used in forensic biology. Forensic biology is a scientific field employing genetic typing of biological evidence found at a crime scene as a means for positively identifying, for example, a perpetrator of a crime. To make such an identification, PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, or semen found at a crime scene. The amplified sequence can then be compared to a standard, thereby allowing identification of the origin of the biological sample.

[0197] The sequences of the present invention can be used to provide polynucleotide reagents, e.g., PCR primers, targeted to specific loci in the human genome, which can enhance the reliability of DNA-based forensic identifications by, for example, providing another “identification marker” (i.e. another DNA sequence that is unique to a particular individual). As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Sequences targeted to noncoding regions of SEQ ID NO:1, SEQ ID NO:7, and SEQ ID NO:25 are particularly appropriate for this use as greater numbers of polymorphisms occur in the noncoding regions, making it easier to differentiate individuals using this technique. Examples of polynucleotide reagents include the CARD-3 or CARD-4L/S sequences or portions thereof, e.g., fragments derived from the noncoding regions of SEQ ID NO:l, SEQ ID NO:7, or SEQ ID NO:25 which have a length of at least 20 or 30 bases.

[0198] The CARD-3 or CARD-4L/S sequences described herein can further be used to provide polynucleotide reagents, e.g., labeled or labelable probes which can be used in, for example, an in situ hybridization technique, to identify a specific tissue, e.g., brain tissue. This can be very useful in cases where a forensic pathologist is presented with a tissue of unknown origin. Panels of such CARD-3 or CARD-4L/S probes can be used to identify tissue by species and/or by organ type.

[0199] In a similar fashion, these reagents, e.g., CARD-3 or CARD-4L/S primers or probes can be used to screen tissue culture for contamination (i.e., screen for the presence of a mixture of different types of cells in a culture).

[0200] C. Predictive Medicine

[0201] The present invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trails are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining CARD-3 or CARD-4L/S protein and/or nucleic acid expression as well as CARD-3 or CARD-4L/S activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant CARD-3 or CARD-4L/S expression or activity. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with CARD-3 or CARD-4L/S protein, nucleic acid expression or activity. For example, mutations in a CARD-3 or CARD-4L/S gene can be assayed in a biological sample. Such-assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with CARD-3 or CARD-4L/S protein, nucleic acid expression or activity.

[0202] Another aspect of the invention provides methods for determining CARD-3 or CARD-4L/S protein, nucleic acid expression or CARD-3 or CARD-4L/S activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as “pharmacogenomics”). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

[0203] Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs or other compounds) on the expression or activity of CARD-3 or CARD-4L/S in clinical trials.

[0204] These and other agents are described in further detail in the following sections.

[0205] 1. Diagnostic Assays

[0206] An exemplary method for detecting the presence or absence of CARD-3 or CARD-4L/S in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting CARD-3 or CARD-4L/S protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes CARD-3 or CARD-4L/S protein such that the presence of CARD-3 or CARD-4L/S is detected in the biological sample. A preferred agent for detecting CARD-3 or CARD-4L/S mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to CARD-3 or CARD-4L/S mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length CARD-3 or CARD-4L/S nucleic acid, such as the nucleic acid of SEQ ID NO: 1 or 3, SEQ ID NO: 7 or 9, SEQ ID NO:25 or 27, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to CARD-3 or CARD-4L/S mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

[0207] A preferred agent for detecting CARD-3 or CARD-4L/S protein is an antibody capable of binding to CARD-3 or CARD-4L/S protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′)₂) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect CARD-3 or CARD-4L/S mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of CARD-3 or CARD-4L/S mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of CARD-3 or CARD-4L/S protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence.

[0208] In vitro techniques for detection of CARD-3 or CARD-4L/S genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of CARD-3 or CARD-4L/S protein include introducing into a subject a labeled anti-CARD-3 or CARD-4L/S antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0209] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

[0210] In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting CARD-3 or CARD-4L/S protein, mRNA, or genomic DNA, such that the presence of CARD-3 or CARD-4L/S protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of CARD-3 or CARD-4L/S protein, mRNA or genomic DNA in the control sample with the presence of CARD-3 or CARD-4L/S protein, mRNA or genomic DNA in the test sample.

[0211] The invention also encompasses kits for detecting the presence of CARD-3 or CARD-4L/S in a biological sample (a test sample). Such kits can be used to determine if a subject is suffering from or is at increased risk of developing a disorder associated with aberrant expression of CARD-3 or CARD-4L/S (e.g., an immunological disorder). For example, the kit can comprise a labeled compound or agent capable of detecting CARD-3 or CARD-4L/S protein or mRNA in a biological sample and means for determining the amount of CARD-3 or CARD-4L/S in the sample (e.g., an anti-CARD-3 or CARD-4L/S antibody or an oligonucleotide probe which binds to DNA encoding CARD-3 or CARD-4L/S, e.g., SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:25 or SEQ ID NO:27). Kits may also include instruction for observing that the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of CARD-3 or CARD-4L/S if the amount of CARD-3 or CARD-4L/S protein or mRNA is above or below a normal level.

[0212] For antibody-based kits, the kit may comprise, for example: (1) a first antibody (e.g., attached to a solid support) which binds to CARD-3 or CARD-4L/S protein; and, optionally, (2) a second, different antibody which binds to CARD-3 or CARD-4L/S protein or the first antibody and is conjugated to a detectable agent.

[0213] For oligonucleotide-based kits, the kit may comprise, for example: (1) a oligonucleotide, e.g., a detectably labelled oligonucleotide, which hybridizes to a CARD-3 or CARD-4L/S nucleic acid sequence or (2) a pair of primers useful for amplifying a CARD-3 or CARD-4L/S nucleic acid molecule;

[0214] The kit may also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit may also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit may also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for observing whether the tested subject is suffering from or is at risk of developing a disorder associated with aberrant expression of CARD-3 or CARD-4L/S.

[0215] 2. Prognostic Assays

[0216] The methods described herein can furthermore be utilized as diagnostic or prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with aberrant CARD-3 or CARD-4L/S expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with CARD-3 or CARD-4L/S protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing such a disease or disorder. Thus, the present invention provides a method in which a test sample is obtained from a subject and CARD-3 or CARD-4L/S protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of CARD-3 or CARD-4L/S protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant CARD-3 or CARD-4L/S expression or activity. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

[0217] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant CARD-3 or CARD-4L/S expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with a specific agent or class of agents (e.g., agents of a type which decrease CARD-3 or CARD-4L/S activity). Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant CARD-3 or CARD-4L/S expression or activity in which a test sample is obtained and CARD-3 or CARD-4L/S protein or nucleic acid is detected (e.g., wherein the presence of CARD-3 or CARD-4L/S protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant CARD-3 or CARD-4L/S expression or activity).

[0218] The methods of the invention can also be used to detect genetic lesions or mutations in a CARD-3 or CARD-4L/S gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a CARD-3 or CARD-4L/S-protein, or the mis-expression of the CARD-3 or CARD-4L/S gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of 1) a deletion of one or more nucleotides from a CARD-3 or CARD-4L/S gene; 2) an addition of one or more nucleotides to a CARD-3 or CARD-4L/S gene; 3) a substitution of one or more nucleotides of a CARD-3 or CARD-4L/S gene, 4) a chromosomal rearrangement of a CARD-3 or CARD-4L/S gene; 5) an alteration in the level of a messenger RNA transcript of a CARD-3 or CARD-4L/S gene, 6) aberrant modification of a CARD-3 or CARD-4L/S gene, such as of the methylation pattern of the genomic DNA, 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a CARD-3 or CARD-4L/S gene, 8) a non-wild type level of a CARD-3 or CARD-4L/S-protein, 9) allelic loss of a CARD-3 or CARD-4L/S gene, and 10) inappropriate post-translational modification of a CARD-3 or CARD-4L/S protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a CARD-3 or CARD-4L/S gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

[0219] In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al. (1988) Science 241:1077-1080; and Nakazawa et al. (1994) Proc. Natl. Acad. Sci. USA 91:360-364), the latter of which can be particularly useful for detecting point mutations in the CARD-3 or CARD-4L/S-gene (see, e.g., Abravaya et al. (1995) Nucleic Acids Res. 23:675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a CARD-3 or CARD-4L/S gene under conditions such that hybridization and amplification of the CARD-3 or CARD-4L/S-gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

[0220] Alternative amplification methods include: self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

[0221] In an alternative embodiment, mutations in a CARD-3 or CARD-4L/S gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

[0222] In other embodiments, genetic mutations in CARD-3 or CARD-4L/S can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotides probes (Cronin et al. (1996) Human Mutation 7:244-255; Kozal et al. (1996) Nature Medicine 2:753-759). For example, genetic mutations in CARD-3 or CARD-4L/S can be identified in two-dimensional arrays containing light-generated DNA probes as described in Cronin et al. supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

[0223] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the CARD-3 or CARD-4L/S gene and detect mutations by comparing the sequence of the sample CARD-3 or CARD-4L/S with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) Proc. Natl. Acad. Sci. USA 74:560) or Sanger ((1977) Proc. Natl. Acad. Sci. USA 74:5463). It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays ((1995) Bio/Techniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT Publication No. WO 94/16101; Cohen et al. (1996) Adv. Chromatogr. 36:127-162; and Griffin et al. (1993) Appl. Biochem. Biotechnol. 38:147-159).

[0224] Other methods for detecting mutations in the CARD-3 or CARD-4L/S gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes (Myers et al. (1985) Science 230:1242). In general, the art technique of “mismatch cleavage” starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type CARD-3 or CARD-4L/S sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digesting the mismatched regions.

[0225] In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton et al (1988) Proc. Natl Acad Sci USA 85:4397; Saleeba et al (1992) Methods Enzymol. 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

[0226] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called “DNA mismatch repair” enzymes) in defined systems for detecting and mapping point mutations in CARD-3 or CARD-4L/S cDNAs obtained from samples of cells. For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662). According to an exemplary embodiment, a probe based on a CARD-3 or CARD-4L/S sequence, e.g., a wild-type CARD-3 or CARD-4L/S sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.

[0227] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in CARD-3 or CARD-4L/S genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc Natl. Acad. Sci USA: 86:2766, see also Cotton (1993) Mutat. Res. 285:125-144; and Hayashi (1992) Genet Anal Tech Appl 9:73-79). Single-stranded DNA fragments of sample and control CARD-3 or CARD-4L/S nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet 7:5).

[0228] In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem 265:12753).

[0229] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al. (1989) Proc. Natl Acad. Sci USA 86:6230). Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

[0230] Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) (Gibbs et al. (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3′ end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11:238). In addition, it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection (Gasparini et al. (1992) Mol. Cell Probes 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad. Sci USA 88:189). In such cases, ligation will occur only if there is a perfect match at the 3′ end of the 5′ sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

[0231] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a CARD-3 or CARD-4L/S gene.

[0232] Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which CARD-3 or CARD-4L/S is expressed may be utilized in the prognostic assays described herein.

[0233] 3. Pharmacogenomics

[0234] Agents, or modulators which have a stimulatory or inhibitory effect on CARD-3 or CARD-4L/S activity (e.g., CARD-3 or CARD-4L/S gene expression) as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (e.g., an immunological disorder) associated with aberrant CARD-3 or CARD-4L/S activity. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of CARD-3 or CARD-4L/S protein, expression of CARD-3 or CARD-4L/S nucleic acid, or mutation content of CARD-3 or CARD-4L/S genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

[0235] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Linder (1997) Clin. Chem. 43(2):254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is haemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

[0236] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2Cl9) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

[0237] Thus, the activity of CARD-3 or CARD-4L/S protein, expression of CARD-3 or CARD-4L/S nucleic acid, or mutation content of CARD-3 or CARD-4L/S genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a CARD-3 or CARD-4L/S modulator, such as a modulator identified by one of the exemplary screening assays described herein.

[0238] 4. Monitoring of Effects During Clinical Trials

[0239] Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of CARD-3 or CARD-4L/S (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase CARD-3 or CARD-4L/S gene expression, protein levels, or upregulate CARD-3 or CARD-4L/S activity, can be monitored in clinical trails of subjects exhibiting decreased CARD-3 or CARD-4L/S gene expression, protein levels, or downregulated CARD-3 or CARD-4L/S activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease CARD-3 or CARD-4L/S gene expression, protein levels, or downregulated CARD-3 or CARD-4L/S activity, can be monitored in clinical trails of subjects exhibiting increased CARD-3 or CARD-4L/S gene expression, protein levels, or upregulated CARD-3 or CARD-4L/S activity. In such clinical trials, the expression or activity of CARD-3 or CARD-4L/S and, preferably, other genes that have been implicated in, for example, a cellular proliferation disorder can be used as a “read out” or markers of the immune responsiveness of a particular cell.

[0240] For example, and not by way of limitation, genes, including CARD-3 or CARD-4L/S, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) which modulates CARD-3 or CARD-4L/S activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of CARD-3 or CARD-4L/S and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of CARD-3 or CARD-4L/S or other genes. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

[0241] In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a CARD-3 or CARD-4L/S protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the CARD-3 or CARD-4L/S protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the CARD-3 or CARD-4L/S protein, mRNA, or genomic DNA in the pre-administration sample with the CARD-3 or CARD-4L/S protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of CARD-3 or CARD-4L/S to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of CARD-3 or CARD-4L/S to lower levels than detected, i.e., to decrease the effectiveness of the agent.

[0242] C. Methods of Treatment

[0243] The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant CARD-3 or CARD-4L/S expression or activity.

[0244] 1. Prophylactic Methods

[0245] In one aspect, the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant CARD-3 or CARD-4L/S expression or activity, by administering to the subject an agent which modulates CARD-3 or CARD-4L/S expression or at least one CARD-3 or CARD-4L/S activity. Subjects at risk for a disease which is caused or contributed to by aberrant CARD-3 or CARD-4L/S expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the CARD-3 or CARD-4L/S aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending on the type of CARD-3 or CARD-4L/S aberrancy, for example, a CARD-3 or CARD-4L/S agonist or CARD-3 or CARD-4L/S antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

[0246] 2. Therapeutic Methods

[0247] Another aspect of the invention pertains to methods of modulating CARD-3 or CARD-4L/S expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of CARD-3 or CARD-4L/S protein activity associated with the cell. An agent that modulates CARD-3 or CARD-4L/S protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a CARD-3 or CARD-4L/S protein, a peptide, a CARD-3 or CARD-4L/S peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more of the biological activities of CARD-3 or CARD-4L/S protein. Examples of such stimulatory agents include active CARD-3 or CARD-4L/S protein and a nucleic acid molecule encoding CARD-3 or CARD-4L/S that has been introduced into the cell. In another embodiment, the agent inhibits one or more of the biological activities of CARD-3 or CARD-4L/S protein. Examples of such inhibitory agents include antisense CARD-3 or CARD-4L/S nucleic acid molecules and anti-CARD-3 or CARD-4L/S antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a CARD-3 or CARD-4L/S protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., upregulates or downregulates) CARD-3 or CARD-4L/S expression or activity. In another embodiment, the method involves administering a CARD-3 or CARD-4L/S protein or nucleic acid molecule as therapy to compensate for reduced or aberrant CARD-3 or CARD-4L/S expression or activity.

[0248] Stimulation of CARD-3 or CARD-4L/S activity is desirable in situations in which CARD-3 or CARD-4L/S is abnormally downregulated and/or in which increased CARD-3 or CARD-4L/S activity is likely to have a beneficial effect. Conversely, inhibition of CARD-3 or CARD-4L/S activity is desirable in situations in which CARD-3 or CARD-4L/S is abnormally upregulated, e.g., in myocardial infarction, and/or in which decreased CARD-3 or CARD-4L/S activity is likely to have a beneficial effect. Since CARD-4L/S may play be involved in the processing of cytokines, inhibiting the activity or expression CARD4-L/S may be beneficial in patients that have aberrant inflammation.

[0249] This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are hereby incorporated by reference.

EXAMPLES Example 1 Isolation and Characterization of full length Human CARD-3 and CARD-4L/S cDNAs.

[0250] A profile of known CARD domains was used to search a proprietary EST and dbEST databases using TBLASTN (Washington University; version 2.0, BLOSUM62 search matix). This search led to the identification of CARD-3.

[0251] Using CARD-3 to search proprietary EST databases another potential CARD EST was found. This EST sequence was used screen a human umbilical vein endothelial library (HUVE) and a clone containing the partial CARD-4S was identified. The human umbilical vein endothelial library was then rescreened using a probe designed against the partial CARD-4S sequence and a clone containing the CARD-4L sequence was identified.

Example 2 Characterization of CARD-3 AND CARD-4L/S Proteins

[0252] In this example, the predicted amino acid sequences of human CARD-3 and CARD-4L/S proteins were compared to amino acid sequences of known proteins and various motifs were identified. For example, the CARD domains of CARD-3 and CARD-4 were aligned (FIG. 7) with the CARD domains of ARC-CARD (SEQ ID NO:31), cIAP1-CARD (SEQ ID NO:32), cIAP1-CARD (SEQ ID NO:33) and cIAP2-CARD (SEQ ID NO:34). In addition, the molecular weight of the human CARD-3 and CARD-4L/S proteins were predicted.

[0253] The human CARD-3 cDNA was isolated as described above (FIG. 1; SEQ ID NO:1) and encodes a 540 amino acid protein (FIG. 2: SEQ ID NO:2). CARD-3 also includes one predicted kinase domain (amino acid 1 to amino acid 300 of SEQ ID NO:2; SEQ ID NO:4), which is followed by a predicted linker domain (amino acid 301 to amino acid 431 of SEQ ID NO:2; SEQ ID NO:5) and a predicted CARD domain (amino acid 432 to amino acid 540 of SEQ ID NO:2, SEQ ID NO:6).

[0254] The human CARD-4L cDNA was isolated as described above (FIG. 3; SEQ ID NO:7) and has a 2859 nucleotide open reading frame (nucleotides 245-3103 of SEQ ID NO:7; SEQ ID NO:9) which encodes a 953 amino acid protein (FIG. 4;SEQ ID NO:8). CARD-4L protein has a predicted CARD domain (amino acids 15-114; SEQ ID NO:10). CARD-4L is also predicted to have a nucleotide binding domain which extends from about amino acid 198 to about amino acid 397 of SEQ ID NO:8; SEQ ID NO:11, a predicted Walker Box “A”, which extends from about amino acid 202 to about amino acid 209 of SEQ ID NO:8; SEQ ID NO:12, a predicted Walker Box “B”, which extends from about amino acid 280 to about amino acid 284, of SEQ ID NO:8; SEQ ID NO:13, a predicted kinase 3a subdomain, which extends from about amino acid 327 to about amino acid 338 of SEQ ID NO:8; SEQ ID NO:14, and ten predicted Leucine-rich repeats which extend from about amino acid 674 to about amino acid 950 of SEQ ID NO:8. The first Leucine-rich repeat is predicted to extend from about amino acid 674 to about amino acid 701 of SEQ ID NO:8; SEQ ID NO:15. The second Leucine-rich repeat is predicted to extend from about amino acid 702 to about amino acid 727 of SEQ ID NO:8; SEQ ID NO:16. The third Leucine-rich repeat is predicted to extend from about amino acid 728 to about amino acid 754 of SEQ ID NO:8; SEQ ID NO:17. The fourth Leucine-rich repeat is predicted to extend from about amino acid 755 to about amino acid 782 of SEQ ID NO:8; SEQ ID NO:18. The fifth Leucine-rich repeat is predicted to extend from about amino acid 783 to about amino acid 810 of SEQ ID NO:8; SEQ ID NO:19. The sixth Leucine-rich repeat is predicted to extend from about amino acid 811 to about amino acid 838 of SEQ ID NO:8; SEQ ID NO:20. The seventh Leucine-rich repeat is predicted to extend from about amino acid 839 to about amino acid 866 of SEQ ID NO:8; SEQ ID NO:21. The eighth Leucine-rich repeat is predicted to extend from about amino acid 867 to about amino acid 894 of SEQ ID NO:8; SEQ ID NO:22. The ninth Leucine-rich repeat is predicted to extend from about amino acid 895 to about amino acid 922 of SEQ ID NO:8; SEQ ID NO:23 and the tenth leucine-rich repeat is predicted to extend from about amino acid 923 to about amino acid 950 of SEQ ID NO:8; SEQ ID NO:24.

[0255] The human partial CARD-4S cDNA isolated as described above (FIG. 5; SEQ ID NO:25) encodes a 490 amino acid protein (FIG. 6; SEQ ID NO:26). CARD-4S includes one predicted partial CARD domain (amino acids 1-74 of SEQ ID NO:26). CARD-4S is also predicted to have a P-Loop which extends from about amino acid 163 to about amino acid 170 of SEQ ID NO:26; SEQ ID NO:29, and a predicted Walker Box “B” which extends form about amino acid 241 to about amino acid 245 of SEQ ID NO:26; SEQ ID NO:30.

[0256] A plot showing the predicted structural features of CARD-4L is presented in FIG. 8. This figure shows the predicted alpha regions (Garnier-Robinson and Chou-Fasman), the predicted beta regions (Garnier-Robinson and Chou-Fasman), the predicted turn regions (Garnier-Robinson and Chou-Fasman) and the predicted coil regions (Garnier-Robinson and Chou-Fasman). Also included in the figure is a hydrophilicity plot (Kyte-Doolittle), the predicted alpha and beta-amphatic regions (Eisenberg), the predicted flexible regions (Karplus-Schulz), the predicted antigenic index (Jameson-Wolf) and the predicted surface probability plot (Emini).

[0257] A plot showing the predicted sturctural features of CARD-4S is also presented in FIG. 9. This figure shows the predicted alpha regions (Garnier-Robinson and Chou-Fasman), the predicted beta regions (Garnier-Robinson and Chou-Fasman), the predicted turn regions (Garnier-Robinson and Chou-Fasman) and the predicted coil regions (Garnier-Robinson and Chou-Fasman). Also included in the figure is a hydrophilicity plot (Kyte-Doolittle), the predicted alpha and beta-amphatic regions (Eisenberg), the predicted flexible regions (Karplus-Schulz), the predicted antigenic index (Jameson-Wolf) and the predicted surface probability plot (Emini).

[0258] The predicted MW of CARD-3 is approximately 61 kDa. The predicted MW of CARD-4L is approximately 108 kDa.

Example 4 Preparation of CARD 3 and CARD-4L/S Proteins

[0259] Recombinant CARD-3 and CARD-4L/S can be produced in a variety of expression systems. For example, the CARD-3 and CARD-4L/S peptides can be expressed as a recombinant glutathione-S-transferase (GST) fusion protein in E. coli and the fusion protein can be isolated and characterized. Specifically, as described above, CARD-3 or CARD-4L/S can be fused to GST and the fusion protein can be expressed in E. coli strain PEB199. Expression of the GST-CARD-3 or GST-CARD-4L/S fusion protein in PEB199 can be induced with IPTG. The recombinant fusion protein can be purified from crude bacterial lysates of the induced PEB199 strain by affinity chromatography on glutathione beads.

1 37 1 1931 DNA Homo sapiens CDS (214)...(1833) 1 ccacgcgtcc ggtcagctct ggttcggaga agcagcggct ggcgtgggcc atccggggaa 60 tgggcgccct cgtgacctag tgttgcgggg caaaaagggt cttgccggcc tcgctcgtgc 120 aggggcgtat ctgggcgcct gagcgcggcg tgggagcctt gggagccgcc gcagcagggg 180 gcacacccgg aaccggcctg agcgcccggg acc atg aac ggg gag gcc atc tgc 234 Met Asn Gly Glu Ala Ile Cys 1 5 agc gcc ctg ccc acc att ccc tac cac aaa ctc gcc gac ctg cgc tac 282 Ser Ala Leu Pro Thr Ile Pro Tyr His Lys Leu Ala Asp Leu Arg Tyr 10 15 20 ctg agc cgc ggc gcc tct ggc act gtg tcg tcc gcc cgc cac gca gac 330 Leu Ser Arg Gly Ala Ser Gly Thr Val Ser Ser Ala Arg His Ala Asp 25 30 35 tgg cgc gtc cag gtg gcc gtg aag cac ctg cac atc cac act ccg ctg 378 Trp Arg Val Gln Val Ala Val Lys His Leu His Ile His Thr Pro Leu 40 45 50 55 ctc gac agt gaa aga aag gat gtc tta aga gaa gct gaa att tta cac 426 Leu Asp Ser Glu Arg Lys Asp Val Leu Arg Glu Ala Glu Ile Leu His 60 65 70 aaa gct aga ttt agt tac att ctt cca att ttg gga att tgc aat gag 474 Lys Ala Arg Phe Ser Tyr Ile Leu Pro Ile Leu Gly Ile Cys Asn Glu 75 80 85 cct gaa ttt ttg gga ata gtt act gaa tac atg cca aat gga tca tta 522 Pro Glu Phe Leu Gly Ile Val Thr Glu Tyr Met Pro Asn Gly Ser Leu 90 95 100 aat gaa ctc cta cat agg aaa act gaa tat cct gat gtt gct tgg cca 570 Asn Glu Leu Leu His Arg Lys Thr Glu Tyr Pro Asp Val Ala Trp Pro 105 110 115 ttg aga ttt cgc atc ctg cat gaa att gcc ctt ggt gta aat tac ctg 618 Leu Arg Phe Arg Ile Leu His Glu Ile Ala Leu Gly Val Asn Tyr Leu 120 125 130 135 cac aat atg act cct cct tta ctt cat cat gac ttg aag act cag aat 666 His Asn Met Thr Pro Pro Leu Leu His His Asp Leu Lys Thr Gln Asn 140 145 150 atc tta ttg gac aat gaa ttt cat gtt aag att gca gat ttt ggt tta 714 Ile Leu Leu Asp Asn Glu Phe His Val Lys Ile Ala Asp Phe Gly Leu 155 160 165 tca aag tgg cgc atg atg tcc ctc tca cag tca cga agt agc aaa tct 762 Ser Lys Trp Arg Met Met Ser Leu Ser Gln Ser Arg Ser Ser Lys Ser 170 175 180 gca cca gaa gga ggg aca att atc tat atg cca cct gaa aac tat gaa 810 Ala Pro Glu Gly Gly Thr Ile Ile Tyr Met Pro Pro Glu Asn Tyr Glu 185 190 195 cct gga caa aaa tca agg gcc agt atc aag cac gat ata tat agc tat 858 Pro Gly Gln Lys Ser Arg Ala Ser Ile Lys His Asp Ile Tyr Ser Tyr 200 205 210 215 gca gtt atc aca tgg gaa gtg tta tcc aga aaa cag cct ttt gaa gat 906 Ala Val Ile Thr Trp Glu Val Leu Ser Arg Lys Gln Pro Phe Glu Asp 220 225 230 gtc acc aat cct ttg cag ata atg tat agt gtg tca caa gga cat cga 954 Val Thr Asn Pro Leu Gln Ile Met Tyr Ser Val Ser Gln Gly His Arg 235 240 245 cct gtt att aat gaa gaa agt ttg cca tat gat ata cct cac cga gca 1002 Pro Val Ile Asn Glu Glu Ser Leu Pro Tyr Asp Ile Pro His Arg Ala 250 255 260 cgt atg atc tct cta ata gaa agt gga tgg gca caa aat cca gat gaa 1050 Arg Met Ile Ser Leu Ile Glu Ser Gly Trp Ala Gln Asn Pro Asp Glu 265 270 275 aga cca tct ttc tta aaa tgt tta ata gaa ctt gaa cca gtt ttg aga 1098 Arg Pro Ser Phe Leu Lys Cys Leu Ile Glu Leu Glu Pro Val Leu Arg 280 285 290 295 aca ttt gaa gag ata act ttt ctt gaa gct gtt att cag cta aag aaa 1146 Thr Phe Glu Glu Ile Thr Phe Leu Glu Ala Val Ile Gln Leu Lys Lys 300 305 310 aca aag tta cag agt gtt tca agt gcc att cac cta tgt gac aag aag 1194 Thr Lys Leu Gln Ser Val Ser Ser Ala Ile His Leu Cys Asp Lys Lys 315 320 325 aaa atg gaa tta tct ctg aac ata cct gta aat cat ggt cca caa gag 1242 Lys Met Glu Leu Ser Leu Asn Ile Pro Val Asn His Gly Pro Gln Glu 330 335 340 gaa tca tgt gga tcc tct cag ctc cat gaa aat agt ggt tct cct gaa 1290 Glu Ser Cys Gly Ser Ser Gln Leu His Glu Asn Ser Gly Ser Pro Glu 345 350 355 act tca agg tcc ctg cca gct cct caa gac aat gat ttt tta tct aga 1338 Thr Ser Arg Ser Leu Pro Ala Pro Gln Asp Asn Asp Phe Leu Ser Arg 360 365 370 375 aaa gct caa gac tgt tat ttt atg aag ctg cat cac tgt cct gga aat 1386 Lys Ala Gln Asp Cys Tyr Phe Met Lys Leu His His Cys Pro Gly Asn 380 385 390 cac agt tgg gat agc acc att tct gga tct caa agg gct gca ttc tgt 1434 His Ser Trp Asp Ser Thr Ile Ser Gly Ser Gln Arg Ala Ala Phe Cys 395 400 405 gat cac aag acc att cca tgc tct tca gca ata ata aat cca ctc tca 1482 Asp His Lys Thr Ile Pro Cys Ser Ser Ala Ile Ile Asn Pro Leu Ser 410 415 420 act gca gga aac tca gaa cgt ctg cag cct ggt ata gcc cag cag tgg 1530 Thr Ala Gly Asn Ser Glu Arg Leu Gln Pro Gly Ile Ala Gln Gln Trp 425 430 435 atc cag agc aaa agg gaa gac att gtg aac caa atg aca gaa gcc tgc 1578 Ile Gln Ser Lys Arg Glu Asp Ile Val Asn Gln Met Thr Glu Ala Cys 440 445 450 455 ctt aac cag tcg cta gat gcc ctt ctg tcc agg gac ttg atc atg aaa 1626 Leu Asn Gln Ser Leu Asp Ala Leu Leu Ser Arg Asp Leu Ile Met Lys 460 465 470 gag gac tat gaa ctt gtt agt acc aag cct aca agg acc tca aaa gtc 1674 Glu Asp Tyr Glu Leu Val Ser Thr Lys Pro Thr Arg Thr Ser Lys Val 475 480 485 aga caa tta cta gac act act gac atc caa gga gaa gaa ttt gcc aaa 1722 Arg Gln Leu Leu Asp Thr Thr Asp Ile Gln Gly Glu Glu Phe Ala Lys 490 495 500 gtt ata gta caa aaa ttg aaa gat aac aaa caa atg ggt ctt cag cct 1770 Val Ile Val Gln Lys Leu Lys Asp Asn Lys Gln Met Gly Leu Gln Pro 505 510 515 tac ccg gaa ata ctt gtg gtt tct aga tca cca tct tta aat tta ctt 1818 Tyr Pro Glu Ile Leu Val Val Ser Arg Ser Pro Ser Leu Asn Leu Leu 520 525 530 535 caa aat aaa agc atg taagtgactg tttttcaaga agaaatgtgt ttcataaaag 1873 Gln Asn Lys Ser Met 540 gatatttata aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa 1931 2 540 PRT Homo sapiens 2 Met Asn Gly Glu Ala Ile Cys Ser Ala Leu Pro Thr Ile Pro Tyr His 1 5 10 15 Lys Leu Ala Asp Leu Arg Tyr Leu Ser Arg Gly Ala Ser Gly Thr Val 20 25 30 Ser Ser Ala Arg His Ala Asp Trp Arg Val Gln Val Ala Val Lys His 35 40 45 Leu His Ile His Thr Pro Leu Leu Asp Ser Glu Arg Lys Asp Val Leu 50 55 60 Arg Glu Ala Glu Ile Leu His Lys Ala Arg Phe Ser Tyr Ile Leu Pro 65 70 75 80 Ile Leu Gly Ile Cys Asn Glu Pro Glu Phe Leu Gly Ile Val Thr Glu 85 90 95 Tyr Met Pro Asn Gly Ser Leu Asn Glu Leu Leu His Arg Lys Thr Glu 100 105 110 Tyr Pro Asp Val Ala Trp Pro Leu Arg Phe Arg Ile Leu His Glu Ile 115 120 125 Ala Leu Gly Val Asn Tyr Leu His Asn Met Thr Pro Pro Leu Leu His 130 135 140 His Asp Leu Lys Thr Gln Asn Ile Leu Leu Asp Asn Glu Phe His Val 145 150 155 160 Lys Ile Ala Asp Phe Gly Leu Ser Lys Trp Arg Met Met Ser Leu Ser 165 170 175 Gln Ser Arg Ser Ser Lys Ser Ala Pro Glu Gly Gly Thr Ile Ile Tyr 180 185 190 Met Pro Pro Glu Asn Tyr Glu Pro Gly Gln Lys Ser Arg Ala Ser Ile 195 200 205 Lys His Asp Ile Tyr Ser Tyr Ala Val Ile Thr Trp Glu Val Leu Ser 210 215 220 Arg Lys Gln Pro Phe Glu Asp Val Thr Asn Pro Leu Gln Ile Met Tyr 225 230 235 240 Ser Val Ser Gln Gly His Arg Pro Val Ile Asn Glu Glu Ser Leu Pro 245 250 255 Tyr Asp Ile Pro His Arg Ala Arg Met Ile Ser Leu Ile Glu Ser Gly 260 265 270 Trp Ala Gln Asn Pro Asp Glu Arg Pro Ser Phe Leu Lys Cys Leu Ile 275 280 285 Glu Leu Glu Pro Val Leu Arg Thr Phe Glu Glu Ile Thr Phe Leu Glu 290 295 300 Ala Val Ile Gln Leu Lys Lys Thr Lys Leu Gln Ser Val Ser Ser Ala 305 310 315 320 Ile His Leu Cys Asp Lys Lys Lys Met Glu Leu Ser Leu Asn Ile Pro 325 330 335 Val Asn His Gly Pro Gln Glu Glu Ser Cys Gly Ser Ser Gln Leu His 340 345 350 Glu Asn Ser Gly Ser Pro Glu Thr Ser Arg Ser Leu Pro Ala Pro Gln 355 360 365 Asp Asn Asp Phe Leu Ser Arg Lys Ala Gln Asp Cys Tyr Phe Met Lys 370 375 380 Leu His His Cys Pro Gly Asn His Ser Trp Asp Ser Thr Ile Ser Gly 385 390 395 400 Ser Gln Arg Ala Ala Phe Cys Asp His Lys Thr Ile Pro Cys Ser Ser 405 410 415 Ala Ile Ile Asn Pro Leu Ser Thr Ala Gly Asn Ser Glu Arg Leu Gln 420 425 430 Pro Gly Ile Ala Gln Gln Trp Ile Gln Ser Lys Arg Glu Asp Ile Val 435 440 445 Asn Gln Met Thr Glu Ala Cys Leu Asn Gln Ser Leu Asp Ala Leu Leu 450 455 460 Ser Arg Asp Leu Ile Met Lys Glu Asp Tyr Glu Leu Val Ser Thr Lys 465 470 475 480 Pro Thr Arg Thr Ser Lys Val Arg Gln Leu Leu Asp Thr Thr Asp Ile 485 490 495 Gln Gly Glu Glu Phe Ala Lys Val Ile Val Gln Lys Leu Lys Asp Asn 500 505 510 Lys Gln Met Gly Leu Gln Pro Tyr Pro Glu Ile Leu Val Val Ser Arg 515 520 525 Ser Pro Ser Leu Asn Leu Leu Gln Asn Lys Ser Met 530 535 540 3 1620 DNA Homo sapiens 3 atgaacgggg aggccatctg cagcgccctg cccaccattc cctaccacaa actcgccgac 60 ctgcgctacc tgagccgcgg cgcctctggc actgtgtcgt ccgcccgcca cgcagactgg 120 cgcgtccagg tggccgtgaa gcacctgcac atccacactc cgctgctcga cagtgaaaga 180 aaggatgtct taagagaagc tgaaatttta cacaaagcta gatttagtta cattcttcca 240 attttgggaa tttgcaatga gcctgaattt ttgggaatag ttactgaata catgccaaat 300 ggatcattaa atgaactcct acataggaaa actgaatatc ctgatgttgc ttggccattg 360 agatttcgca tcctgcatga aattgccctt ggtgtaaatt acctgcacaa tatgactcct 420 cctttacttc atcatgactt gaagactcag aatatcttat tggacaatga atttcatgtt 480 aagattgcag attttggttt atcaaagtgg cgcatgatgt ccctctcaca gtcacgaagt 540 agcaaatctg caccagaagg agggacaatt atctatatgc cacctgaaaa ctatgaacct 600 ggacaaaaat caagggccag tatcaagcac gatatatata gctatgcagt tatcacatgg 660 gaagtgttat ccagaaaaca gccttttgaa gatgtcacca atcctttgca gataatgtat 720 agtgtgtcac aaggacatcg acctgttatt aatgaagaaa gtttgccata tgatatacct 780 caccgagcac gtatgatctc tctaatagaa agtggatggg cacaaaatcc agatgaaaga 840 ccatctttct taaaatgttt aatagaactt gaaccagttt tgagaacatt tgaagagata 900 acttttcttg aagctgttat tcagctaaag aaaacaaagt tacagagtgt ttcaagtgcc 960 attcacctat gtgacaagaa gaaaatggaa ttatctctga acatacctgt aaatcatggt 1020 ccacaagagg aatcatgtgg atcctctcag ctccatgaaa atagtggttc tcctgaaact 1080 tcaaggtccc tgccagctcc tcaagacaat gattttttat ctagaaaagc tcaagactgt 1140 tattttatga agctgcatca ctgtcctgga aatcacagtt gggatagcac catttctgga 1200 tctcaaaggg ctgcattctg tgatcacaag accattccat gctcttcagc aataataaat 1260 ccactctcaa ctgcaggaaa ctcagaacgt ctgcagcctg gtatagccca gcagtggatc 1320 cagagcaaaa gggaagacat tgtgaaccaa atgacagaag cctgccttaa ccagtcgcta 1380 gatgcccttc tgtccaggga cttgatcatg aaagaggact atgaacttgt tagtaccaag 1440 cctacaagga cctcaaaagt cagacaatta ctagacacta ctgacatcca aggagaagaa 1500 tttgccaaag ttatagtaca aaaattgaaa gataacaaac aaatgggtct tcagccttac 1560 ccggaaatac ttgtggtttc tagatcacca tctttaaatt tacttcaaaa taaaagcatg 1620 4 300 PRT Homo sapiens 4 Met Asn Gly Glu Ala Ile Cys Ser Ala Leu Pro Thr Ile Pro Tyr His 1 5 10 15 Lys Leu Ala Asp Leu Arg Tyr Leu Ser Arg Gly Ala Ser Gly Thr Val 20 25 30 Ser Ser Ala Arg His Ala Asp Trp Arg Val Gln Val Ala Val Lys His 35 40 45 Leu His Ile His Thr Pro Leu Leu Asp Ser Glu Arg Lys Asp Val Leu 50 55 60 Arg Glu Ala Glu Ile Leu His Lys Ala Arg Phe Ser Tyr Ile Leu Pro 65 70 75 80 Ile Leu Gly Ile Cys Asn Glu Pro Glu Phe Leu Gly Ile Val Thr Glu 85 90 95 Tyr Met Pro Asn Gly Ser Leu Asn Glu Leu Leu His Arg Lys Thr Glu 100 105 110 Tyr Pro Asp Val Ala Trp Pro Leu Arg Phe Arg Ile Leu His Glu Ile 115 120 125 Ala Leu Gly Val Asn Tyr Leu His Asn Met Thr Pro Pro Leu Leu His 130 135 140 His Asp Leu Lys Thr Gln Asn Ile Leu Leu Asp Asn Glu Phe His Val 145 150 155 160 Lys Ile Ala Asp Phe Gly Leu Ser Lys Trp Arg Met Met Ser Leu Ser 165 170 175 Gln Ser Arg Ser Ser Lys Ser Ala Pro Glu Gly Gly Thr Ile Ile Tyr 180 185 190 Met Pro Pro Glu Asn Tyr Glu Pro Gly Gln Lys Ser Arg Ala Ser Ile 195 200 205 Lys His Asp Ile Tyr Ser Tyr Ala Val Ile Thr Trp Glu Val Leu Ser 210 215 220 Arg Lys Gln Pro Phe Glu Asp Val Thr Asn Pro Leu Gln Ile Met Tyr 225 230 235 240 Ser Val Ser Gln Gly His Arg Pro Val Ile Asn Glu Glu Ser Leu Pro 245 250 255 Tyr Asp Ile Pro His Arg Ala Arg Met Ile Ser Leu Ile Glu Ser Gly 260 265 270 Trp Ala Gln Asn Pro Asp Glu Arg Pro Ser Phe Leu Lys Cys Leu Ile 275 280 285 Glu Leu Glu Pro Val Leu Arg Thr Phe Glu Glu Ile 290 295 300 5 131 PRT Homo sapiens 5 Thr Phe Leu Glu Ala Val Ile Gln Leu Lys Lys Thr Lys Leu Gln Ser 1 5 10 15 Val Ser Ser Ala Ile His Leu Cys Asp Lys Lys Lys Met Glu Leu Ser 20 25 30 Leu Asn Ile Pro Val Asn His Gly Pro Gln Glu Glu Ser Cys Gly Ser 35 40 45 Ser Gln Leu His Glu Asn Ser Gly Ser Pro Glu Thr Ser Arg Ser Leu 50 55 60 Pro Ala Pro Gln Asp Asn Asp Phe Leu Ser Arg Lys Ala Gln Asp Cys 65 70 75 80 Tyr Phe Met Lys Leu His His Cys Pro Gly Asn His Ser Trp Asp Ser 85 90 95 Thr Ile Ser Gly Ser Gln Arg Ala Ala Phe Cys Asp His Lys Thr Ile 100 105 110 Pro Cys Ser Ser Ala Ile Ile Asn Pro Leu Ser Thr Ala Gly Asn Ser 115 120 125 Glu Arg Leu 130 6 109 PRT Homo sapiens 6 Gln Pro Gly Ile Ala Gln Gln Trp Ile Gln Ser Lys Arg Glu Asp Ile 1 5 10 15 Val Asn Gln Met Thr Glu Ala Cys Leu Asn Gln Ser Leu Asp Ala Leu 20 25 30 Leu Ser Arg Asp Leu Ile Met Lys Glu Asp Tyr Glu Leu Val Ser Thr 35 40 45 Lys Pro Thr Arg Thr Ser Lys Val Arg Gln Leu Leu Asp Thr Thr Asp 50 55 60 Ile Gln Gly Glu Glu Phe Ala Lys Val Ile Val Gln Lys Leu Lys Asp 65 70 75 80 Asn Lys Gln Met Gly Leu Gln Pro Tyr Pro Glu Ile Leu Val Val Ser 85 90 95 Arg Ser Pro Ser Leu Asn Leu Leu Gln Asn Lys Ser Met 100 105 7 3382 DNA Homo sapiens CDS (245)...(3103) 7 tttttatggg aatcgcagct tggaagagac agarcaattc cagaawtaaa ttgraattga 60 agatttaacc aatgttgttt taaaatattc taacttcaaa gaatgatgcc agaacttwaa 120 aagggrctgc gcagagtagc aggggccctg gagggcgcgg cctgaatcct gattgccctt 180 ctgctgagag gacacacgca gctgaagatg aatttgggaa aagtagccgc ttgctacttt 240 aact atg gaa gag cag ggc cac agt gag atg gaa ata atc cca tca gag 289 Met Glu Glu Gln Gly His Ser Glu Met Glu Ile Ile Pro Ser Glu 1 5 10 15 tct cac ccc cac att caa tta ctg aaa agc aat cgg gaa ctt ctg gtc 337 Ser His Pro His Ile Gln Leu Leu Lys Ser Asn Arg Glu Leu Leu Val 20 25 30 act cac atc cgc aat act cag tgt ctg gtg gac aac ttg ctg aag aat 385 Thr His Ile Arg Asn Thr Gln Cys Leu Val Asp Asn Leu Leu Lys Asn 35 40 45 gac tac ttc tcg gcc gaa gat gcg gag att gtg tgt gcc tgc ccc acc 433 Asp Tyr Phe Ser Ala Glu Asp Ala Glu Ile Val Cys Ala Cys Pro Thr 50 55 60 cag cct gac aag gtc cgc aaa att ctg gac ctg gta cag agc aag ggc 481 Gln Pro Asp Lys Val Arg Lys Ile Leu Asp Leu Val Gln Ser Lys Gly 65 70 75 gag gag gtg tcc gag ttc ttc ctc tac ttg ctc cag caa ctc gca gat 529 Glu Glu Val Ser Glu Phe Phe Leu Tyr Leu Leu Gln Gln Leu Ala Asp 80 85 90 95 gcc tac gtg gac ctc agg cct tgg ctg ctg gag atc ggc ttc tcc cct 577 Ala Tyr Val Asp Leu Arg Pro Trp Leu Leu Glu Ile Gly Phe Ser Pro 100 105 110 tcc ctg ctc act cag agc aaa gtc gtg gtc aac act gac cca gtg agc 625 Ser Leu Leu Thr Gln Ser Lys Val Val Val Asn Thr Asp Pro Val Ser 115 120 125 agg tat acc cag cag ctg cga cac cat ctg ggc cgt gac tcc aag ttc 673 Arg Tyr Thr Gln Gln Leu Arg His His Leu Gly Arg Asp Ser Lys Phe 130 135 140 gtg ctg tgc tat gcc cag aag gag gag ctg ctg ctg gag gag atc tac 721 Val Leu Cys Tyr Ala Gln Lys Glu Glu Leu Leu Leu Glu Glu Ile Tyr 145 150 155 atg gac acc atc atg gag ctg gtt ggc ttc agc aat gag agc ctg ggc 769 Met Asp Thr Ile Met Glu Leu Val Gly Phe Ser Asn Glu Ser Leu Gly 160 165 170 175 agc ctg aac agc ctg gcc tgc ctc ctg gac cac acc acc ggc atc ctc 817 Ser Leu Asn Ser Leu Ala Cys Leu Leu Asp His Thr Thr Gly Ile Leu 180 185 190 aat gag cag ggt gag acc atc ttc atc ctg ggt gat gct ggg gtg ggc 865 Asn Glu Gln Gly Glu Thr Ile Phe Ile Leu Gly Asp Ala Gly Val Gly 195 200 205 aag tcc atg ctg cta cag cgg ctg cag agc ctc tgg gcc acg ggc cgg 913 Lys Ser Met Leu Leu Gln Arg Leu Gln Ser Leu Trp Ala Thr Gly Arg 210 215 220 cta gac gca ggg gtc aaa ttc ttc ttc cac ttt cgc tgc cgc atg ttc 961 Leu Asp Ala Gly Val Lys Phe Phe Phe His Phe Arg Cys Arg Met Phe 225 230 235 agc tgc ttc aag gaa agt gac agg ctg tgt ctg cag gac ctg ctc ttc 1009 Ser Cys Phe Lys Glu Ser Asp Arg Leu Cys Leu Gln Asp Leu Leu Phe 240 245 250 255 aag cac tac tgc tac cca gag cgg gac ccc gag gag gtg ttt gcc ttc 1057 Lys His Tyr Cys Tyr Pro Glu Arg Asp Pro Glu Glu Val Phe Ala Phe 260 265 270 ctg ctg cgc ttc ccc cac gtg gcc ctc ttc acc ttc gat ggc ctg gac 1105 Leu Leu Arg Phe Pro His Val Ala Leu Phe Thr Phe Asp Gly Leu Asp 275 280 285 gag ctg cac tcg gac ttg gac ctg agc cgc gtg cct gac agc tcc tgc 1153 Glu Leu His Ser Asp Leu Asp Leu Ser Arg Val Pro Asp Ser Ser Cys 290 295 300 ccc tgg gag cct gcc cac ccc ctg gtc ttg ctg gcc aac ctg ctc agt 1201 Pro Trp Glu Pro Ala His Pro Leu Val Leu Leu Ala Asn Leu Leu Ser 305 310 315 ggg aag ctg ctc aag ggg gct agc aag ctg ctc aca gcc cgc aca ggc 1249 Gly Lys Leu Leu Lys Gly Ala Ser Lys Leu Leu Thr Ala Arg Thr Gly 320 325 330 335 atc gag gtc ccg cgc cag ttc ctg cgg aag aag gtg ctt ctc cgg ggc 1297 Ile Glu Val Pro Arg Gln Phe Leu Arg Lys Lys Val Leu Leu Arg Gly 340 345 350 ttc tcc ccc agc cac ctg cgc gcc tat gcc agg agg atg ttc ccc gag 1345 Phe Ser Pro Ser His Leu Arg Ala Tyr Ala Arg Arg Met Phe Pro Glu 355 360 365 cgg gcc ctg cag gac cgc ctg ctg agc cag ctg gag gcc aac ccc aac 1393 Arg Ala Leu Gln Asp Arg Leu Leu Ser Gln Leu Glu Ala Asn Pro Asn 370 375 380 ctc tgc agc ctg tgc tct gtg ccc ctc ttc tgc tgg atc atc ttc cgg 1441 Leu Cys Ser Leu Cys Ser Val Pro Leu Phe Cys Trp Ile Ile Phe Arg 385 390 395 tgc ttc cag cac ttc cgt gct gcc ttt gaa ggc tca cca cag ctg ccc 1489 Cys Phe Gln His Phe Arg Ala Ala Phe Glu Gly Ser Pro Gln Leu Pro 400 405 410 415 gac tgc acg atg acc ctg aca gat gtc ttc ctc ctg gtc act gag gtc 1537 Asp Cys Thr Met Thr Leu Thr Asp Val Phe Leu Leu Val Thr Glu Val 420 425 430 cat ctg aac agg atg cag ccc agc agc ctg gtg cag cgg aac aca cgc 1585 His Leu Asn Arg Met Gln Pro Ser Ser Leu Val Gln Arg Asn Thr Arg 435 440 445 agc cca gtg gag acc ctc cac gcc ggc cgg gac act ctg tgc tcg ctg 1633 Ser Pro Val Glu Thr Leu His Ala Gly Arg Asp Thr Leu Cys Ser Leu 450 455 460 ggg cag gtg gcc cac cgg ggc atg gag aag agc ctc ttt gtc ttc acc 1681 Gly Gln Val Ala His Arg Gly Met Glu Lys Ser Leu Phe Val Phe Thr 465 470 475 cag gag gag gtg cag gcc tcc ggg ctg cag gag aga gac atg cag ctg 1729 Gln Glu Glu Val Gln Ala Ser Gly Leu Gln Glu Arg Asp Met Gln Leu 480 485 490 495 ggc ttc ctg cgg gct ttg ccg gag ctg ggc ccc ggg ggt gac cag cag 1777 Gly Phe Leu Arg Ala Leu Pro Glu Leu Gly Pro Gly Gly Asp Gln Gln 500 505 510 tcc tat gag ttt ttc cac ctc acc ctc cag gcc ttc ttt aca gcc ttc 1825 Ser Tyr Glu Phe Phe His Leu Thr Leu Gln Ala Phe Phe Thr Ala Phe 515 520 525 ttc ctc gtg ctg gac gac agg gtg ggc act cag gag ctg ctc agg ttc 1873 Phe Leu Val Leu Asp Asp Arg Val Gly Thr Gln Glu Leu Leu Arg Phe 530 535 540 ttc cag gag tgg atg ccc cct gcg ggg gca gcg acc acg tcc tgc tat 1921 Phe Gln Glu Trp Met Pro Pro Ala Gly Ala Ala Thr Thr Ser Cys Tyr 545 550 555 cct ccc ttc ctc ccg ttc cag tgc ctg cag ggc agt ggt ccg gcg cgg 1969 Pro Pro Phe Leu Pro Phe Gln Cys Leu Gln Gly Ser Gly Pro Ala Arg 560 565 570 575 gaa gac ctc ttc aag aac aag gat cac ttc cag ttc acc aac ctc ttc 2017 Glu Asp Leu Phe Lys Asn Lys Asp His Phe Gln Phe Thr Asn Leu Phe 580 585 590 ctg tgc ggg ctg ttg tcc aaa gcc aaa cag aaa ctc ctg cgg cat ctg 2065 Leu Cys Gly Leu Leu Ser Lys Ala Lys Gln Lys Leu Leu Arg His Leu 595 600 605 gtg ccc gcg gca gcc ctg agg aga aag cgc aag gcc ctg tgg gca cac 2113 Val Pro Ala Ala Ala Leu Arg Arg Lys Arg Lys Ala Leu Trp Ala His 610 615 620 ctg ttt tcc agc ctg cgg ggc tac ctg aag agc ctg ccc cgc gtt cag 2161 Leu Phe Ser Ser Leu Arg Gly Tyr Leu Lys Ser Leu Pro Arg Val Gln 625 630 635 gtc gaa agc ttc aac cag gtg cag gcc atg ccc acg ttc atc tgg atg 2209 Val Glu Ser Phe Asn Gln Val Gln Ala Met Pro Thr Phe Ile Trp Met 640 645 650 655 ctg cgc tgc atc tac gag aca cag agc cag aag gtg ggg cag ctg gcg 2257 Leu Arg Cys Ile Tyr Glu Thr Gln Ser Gln Lys Val Gly Gln Leu Ala 660 665 670 gcc agg ggc atc tgc gcc aac tac ctc aag ctg acc tac tgc aac gcc 2305 Ala Arg Gly Ile Cys Ala Asn Tyr Leu Lys Leu Thr Tyr Cys Asn Ala 675 680 685 tgc tcg gcc gac tgc agc gcc ctc tcc ttc gtc ctg cat cac ttc ccc 2353 Cys Ser Ala Asp Cys Ser Ala Leu Ser Phe Val Leu His His Phe Pro 690 695 700 aag cgg ctg gcc cta gac cta gac aac aac aat ctc aac gac tac ggc 2401 Lys Arg Leu Ala Leu Asp Leu Asp Asn Asn Asn Leu Asn Asp Tyr Gly 705 710 715 gtg cgg gag ctg cag ccc tgc ttc agc cgc ctc act gtt ctc aga ctc 2449 Val Arg Glu Leu Gln Pro Cys Phe Ser Arg Leu Thr Val Leu Arg Leu 720 725 730 735 agc gta aac cag atc act gac ggt ggg gta aag gtg cta agc gaa gag 2497 Ser Val Asn Gln Ile Thr Asp Gly Gly Val Lys Val Leu Ser Glu Glu 740 745 750 ctg acc aaa tac aaa att gtg acc tat ttg ggt tta tac aac aac cag 2545 Leu Thr Lys Tyr Lys Ile Val Thr Tyr Leu Gly Leu Tyr Asn Asn Gln 755 760 765 atc acc gat gtc gga gcc agg tac gtc acc aaa atc ctg gat gaa tgc 2593 Ile Thr Asp Val Gly Ala Arg Tyr Val Thr Lys Ile Leu Asp Glu Cys 770 775 780 aaa ggc ctc acg cat ctt aaa ctg gga aaa aac aaa ata aca agt gaa 2641 Lys Gly Leu Thr His Leu Lys Leu Gly Lys Asn Lys Ile Thr Ser Glu 785 790 795 gga ggg aag tat ctc gcc ctg gct gtg aag aac agc aaa tca atc tct 2689 Gly Gly Lys Tyr Leu Ala Leu Ala Val Lys Asn Ser Lys Ser Ile Ser 800 805 810 815 gag gtt ggg atg tgg ggc aat caa gtt ggg gat gaa gga gca aaa gcc 2737 Glu Val Gly Met Trp Gly Asn Gln Val Gly Asp Glu Gly Ala Lys Ala 820 825 830 ttc gca gag gct ctg cgg aac cac ccc agc ttg acc acc ctg agt ctt 2785 Phe Ala Glu Ala Leu Arg Asn His Pro Ser Leu Thr Thr Leu Ser Leu 835 840 845 gcg tcc aac ggc atc tcc aca gaa gga gga aag agc ctt gcg agg gcc 2833 Ala Ser Asn Gly Ile Ser Thr Glu Gly Gly Lys Ser Leu Ala Arg Ala 850 855 860 ctg cag cag aac acg tct cta gaa ata ctg tgg ctg acc caa aat gaa 2881 Leu Gln Gln Asn Thr Ser Leu Glu Ile Leu Trp Leu Thr Gln Asn Glu 865 870 875 ctc aac gat gaa gtg gca gag agt ttg gca gaa atg ttg aaa gtc aac 2929 Leu Asn Asp Glu Val Ala Glu Ser Leu Ala Glu Met Leu Lys Val Asn 880 885 890 895 cag acg tta aag cat tta tgg ctt atc cag aat cag atc aca gct aag 2977 Gln Thr Leu Lys His Leu Trp Leu Ile Gln Asn Gln Ile Thr Ala Lys 900 905 910 ggg act gcc cag ctg gca gat gcg tta cag agc aac act ggc ata aca 3025 Gly Thr Ala Gln Leu Ala Asp Ala Leu Gln Ser Asn Thr Gly Ile Thr 915 920 925 gag att tgc cta aat gga aac ctg ata aaa cca gag gag gcc aaa gtc 3073 Glu Ile Cys Leu Asn Gly Asn Leu Ile Lys Pro Glu Glu Ala Lys Val 930 935 940 tat gaa gat gag aag cgg att atc tgt ttc tgagaggatg ctttcctgtt 3123 Tyr Glu Asp Glu Lys Arg Ile Ile Cys Phe 945 950 catggggttt ttgccctgga gcctcagcag caaatgccac tctgggcagt cttttgtgtc 3183 agtgtcttaa aggggcctgc gcaggcggga ctatcaggag tccactgcct ycatgatgca 3243 agccagcttc ctgtgcagaa ggtctggtcg gcaaactccc taagtacccg ctacaattct 3303 gcagaaaaag aatgtgtctt gcgagctgtt gtagttacag taaatacact gtgaagagaa 3363 aaaaaaaacg gacgcgtgg 3382 8 953 PRT Homo sapiens 8 Met Glu Glu Gln Gly His Ser Glu Met Glu Ile Ile Pro Ser Glu Ser 1 5 10 15 His Pro His Ile Gln Leu Leu Lys Ser Asn Arg Glu Leu Leu Val Thr 20 25 30 His Ile Arg Asn Thr Gln Cys Leu Val Asp Asn Leu Leu Lys Asn Asp 35 40 45 Tyr Phe Ser Ala Glu Asp Ala Glu Ile Val Cys Ala Cys Pro Thr Gln 50 55 60 Pro Asp Lys Val Arg Lys Ile Leu Asp Leu Val Gln Ser Lys Gly Glu 65 70 75 80 Glu Val Ser Glu Phe Phe Leu Tyr Leu Leu Gln Gln Leu Ala Asp Ala 85 90 95 Tyr Val Asp Leu Arg Pro Trp Leu Leu Glu Ile Gly Phe Ser Pro Ser 100 105 110 Leu Leu Thr Gln Ser Lys Val Val Val Asn Thr Asp Pro Val Ser Arg 115 120 125 Tyr Thr Gln Gln Leu Arg His His Leu Gly Arg Asp Ser Lys Phe Val 130 135 140 Leu Cys Tyr Ala Gln Lys Glu Glu Leu Leu Leu Glu Glu Ile Tyr Met 145 150 155 160 Asp Thr Ile Met Glu Leu Val Gly Phe Ser Asn Glu Ser Leu Gly Ser 165 170 175 Leu Asn Ser Leu Ala Cys Leu Leu Asp His Thr Thr Gly Ile Leu Asn 180 185 190 Glu Gln Gly Glu Thr Ile Phe Ile Leu Gly Asp Ala Gly Val Gly Lys 195 200 205 Ser Met Leu Leu Gln Arg Leu Gln Ser Leu Trp Ala Thr Gly Arg Leu 210 215 220 Asp Ala Gly Val Lys Phe Phe Phe His Phe Arg Cys Arg Met Phe Ser 225 230 235 240 Cys Phe Lys Glu Ser Asp Arg Leu Cys Leu Gln Asp Leu Leu Phe Lys 245 250 255 His Tyr Cys Tyr Pro Glu Arg Asp Pro Glu Glu Val Phe Ala Phe Leu 260 265 270 Leu Arg Phe Pro His Val Ala Leu Phe Thr Phe Asp Gly Leu Asp Glu 275 280 285 Leu His Ser Asp Leu Asp Leu Ser Arg Val Pro Asp Ser Ser Cys Pro 290 295 300 Trp Glu Pro Ala His Pro Leu Val Leu Leu Ala Asn Leu Leu Ser Gly 305 310 315 320 Lys Leu Leu Lys Gly Ala Ser Lys Leu Leu Thr Ala Arg Thr Gly Ile 325 330 335 Glu Val Pro Arg Gln Phe Leu Arg Lys Lys Val Leu Leu Arg Gly Phe 340 345 350 Ser Pro Ser His Leu Arg Ala Tyr Ala Arg Arg Met Phe Pro Glu Arg 355 360 365 Ala Leu Gln Asp Arg Leu Leu Ser Gln Leu Glu Ala Asn Pro Asn Leu 370 375 380 Cys Ser Leu Cys Ser Val Pro Leu Phe Cys Trp Ile Ile Phe Arg Cys 385 390 395 400 Phe Gln His Phe Arg Ala Ala Phe Glu Gly Ser Pro Gln Leu Pro Asp 405 410 415 Cys Thr Met Thr Leu Thr Asp Val Phe Leu Leu Val Thr Glu Val His 420 425 430 Leu Asn Arg Met Gln Pro Ser Ser Leu Val Gln Arg Asn Thr Arg Ser 435 440 445 Pro Val Glu Thr Leu His Ala Gly Arg Asp Thr Leu Cys Ser Leu Gly 450 455 460 Gln Val Ala His Arg Gly Met Glu Lys Ser Leu Phe Val Phe Thr Gln 465 470 475 480 Glu Glu Val Gln Ala Ser Gly Leu Gln Glu Arg Asp Met Gln Leu Gly 485 490 495 Phe Leu Arg Ala Leu Pro Glu Leu Gly Pro Gly Gly Asp Gln Gln Ser 500 505 510 Tyr Glu Phe Phe His Leu Thr Leu Gln Ala Phe Phe Thr Ala Phe Phe 515 520 525 Leu Val Leu Asp Asp Arg Val Gly Thr Gln Glu Leu Leu Arg Phe Phe 530 535 540 Gln Glu Trp Met Pro Pro Ala Gly Ala Ala Thr Thr Ser Cys Tyr Pro 545 550 555 560 Pro Phe Leu Pro Phe Gln Cys Leu Gln Gly Ser Gly Pro Ala Arg Glu 565 570 575 Asp Leu Phe Lys Asn Lys Asp His Phe Gln Phe Thr Asn Leu Phe Leu 580 585 590 Cys Gly Leu Leu Ser Lys Ala Lys Gln Lys Leu Leu Arg His Leu Val 595 600 605 Pro Ala Ala Ala Leu Arg Arg Lys Arg Lys Ala Leu Trp Ala His Leu 610 615 620 Phe Ser Ser Leu Arg Gly Tyr Leu Lys Ser Leu Pro Arg Val Gln Val 625 630 635 640 Glu Ser Phe Asn Gln Val Gln Ala Met Pro Thr Phe Ile Trp Met Leu 645 650 655 Arg Cys Ile Tyr Glu Thr Gln Ser Gln Lys Val Gly Gln Leu Ala Ala 660 665 670 Arg Gly Ile Cys Ala Asn Tyr Leu Lys Leu Thr Tyr Cys Asn Ala Cys 675 680 685 Ser Ala Asp Cys Ser Ala Leu Ser Phe Val Leu His His Phe Pro Lys 690 695 700 Arg Leu Ala Leu Asp Leu Asp Asn Asn Asn Leu Asn Asp Tyr Gly Val 705 710 715 720 Arg Glu Leu Gln Pro Cys Phe Ser Arg Leu Thr Val Leu Arg Leu Ser 725 730 735 Val Asn Gln Ile Thr Asp Gly Gly Val Lys Val Leu Ser Glu Glu Leu 740 745 750 Thr Lys Tyr Lys Ile Val Thr Tyr Leu Gly Leu Tyr Asn Asn Gln Ile 755 760 765 Thr Asp Val Gly Ala Arg Tyr Val Thr Lys Ile Leu Asp Glu Cys Lys 770 775 780 Gly Leu Thr His Leu Lys Leu Gly Lys Asn Lys Ile Thr Ser Glu Gly 785 790 795 800 Gly Lys Tyr Leu Ala Leu Ala Val Lys Asn Ser Lys Ser Ile Ser Glu 805 810 815 Val Gly Met Trp Gly Asn Gln Val Gly Asp Glu Gly Ala Lys Ala Phe 820 825 830 Ala Glu Ala Leu Arg Asn His Pro Ser Leu Thr Thr Leu Ser Leu Ala 835 840 845 Ser Asn Gly Ile Ser Thr Glu Gly Gly Lys Ser Leu Ala Arg Ala Leu 850 855 860 Gln Gln Asn Thr Ser Leu Glu Ile Leu Trp Leu Thr Gln Asn Glu Leu 865 870 875 880 Asn Asp Glu Val Ala Glu Ser Leu Ala Glu Met Leu Lys Val Asn Gln 885 890 895 Thr Leu Lys His Leu Trp Leu Ile Gln Asn Gln Ile Thr Ala Lys Gly 900 905 910 Thr Ala Gln Leu Ala Asp Ala Leu Gln Ser Asn Thr Gly Ile Thr Glu 915 920 925 Ile Cys Leu Asn Gly Asn Leu Ile Lys Pro Glu Glu Ala Lys Val Tyr 930 935 940 Glu Asp Glu Lys Arg Ile Ile Cys Phe 945 950 9 2859 DNA Homo sapiens 9 atggaagagc agggccacag tgagatggaa ataatcccat cagagtctca cccccacatt 60 caattactga aaagcaatcg ggaacttctg gtcactcaca tccgcaatac tcagtgtctg 120 gtggacaact tgctgaagaa tgactacttc tcggccgaag atgcggagat tgtgtgtgcc 180 tgccccaccc agcctgacaa ggtccgcaaa attctggacc tggtacagag caagggcgag 240 gaggtgtccg agttcttcct ctacttgctc cagcaactcg cagatgccta cgtggacctc 300 aggccttggc tgctggagat cggcttctcc ccttccctgc tcactcagag caaagtcgtg 360 gtcaacactg acccagtgag caggtatacc cagcagctgc gacaccatct gggccgtgac 420 tccaagttcg tgctgtgcta tgcccagaag gaggagctgc tgctggagga gatctacatg 480 gacaccatca tggagctggt tggcttcagc aatgagagcc tgggcagcct gaacagcctg 540 gcctgcctcc tggaccacac caccggcatc ctcaatgagc agggtgagac catcttcatc 600 ctgggtgatg ctggggtggg caagtccatg ctgctacagc ggctgcagag cctctgggcc 660 acgggccggc tagacgcagg ggtcaaattc ttcttccact ttcgctgccg catgttcagc 720 tgcttcaagg aaagtgacag gctgtgtctg caggacctgc tcttcaagca ctactgctac 780 ccagagcggg accccgagga ggtgtttgcc ttcctgctgc gcttccccca cgtggccctc 840 ttcaccttcg atggcctgga cgagctgcac tcggacttgg acctgagccg cgtgcctgac 900 agctcctgcc cctgggagcc tgcccacccc ctggtcttgc tggccaacct gctcagtggg 960 aagctgctca agggggctag caagctgctc acagcccgca caggcatcga ggtcccgcgc 1020 cagttcctgc ggaagaaggt gcttctccgg ggcttctccc ccagccacct gcgcgcctat 1080 gccaggagga tgttccccga gcgggccctg caggaccgcc tgctgagcca gctggaggcc 1140 aaccccaacc tctgcagcct gtgctctgtg cccctcttct gctggatcat cttccggtgc 1200 ttccagcact tccgtgctgc ctttgaaggc tcaccacagc tgcccgactg cacgatgacc 1260 ctgacagatg tcttcctcct ggtcactgag gtccatctga acaggatgca gcccagcagc 1320 ctggtgcagc ggaacacacg cagcccagtg gagaccctcc acgccggccg ggacactctg 1380 tgctcgctgg ggcaggtggc ccaccggggc atggagaaga gcctctttgt cttcacccag 1440 gaggaggtgc aggcctccgg gctgcaggag agagacatgc agctgggctt cctgcgggct 1500 ttgccggagc tgggccccgg gggtgaccag cagtcctatg agtttttcca cctcaccctc 1560 caggccttct ttacagcctt cttcctcgtg ctggacgaca gggtgggcac tcaggagctg 1620 ctcaggttct tccaggagtg gatgccccct gcgggggcag cgaccacgtc ctgctatcct 1680 cccttcctcc cgttccagtg cctgcagggc agtggtccgg cgcgggaaga cctcttcaag 1740 aacaaggatc acttccagtt caccaacctc ttcctgtgcg ggctgttgtc caaagccaaa 1800 cagaaactcc tgcggcatct ggtgcccgcg gcagccctga ggagaaagcg caaggccctg 1860 tgggcacacc tgttttccag cctgcggggc tacctgaaga gcctgccccg cgttcaggtc 1920 gaaagcttca accaggtgca ggccatgccc acgttcatct ggatgctgcg ctgcatctac 1980 gagacacaga gccagaaggt ggggcagctg gcggccaggg gcatctgcgc caactacctc 2040 aagctgacct actgcaacgc ctgctcggcc gactgcagcg ccctctcctt cgtcctgcat 2100 cacttcccca agcggctggc cctagaccta gacaacaaca atctcaacga ctacggcgtg 2160 cgggagctgc agccctgctt cagccgcctc actgttctca gactcagcgt aaaccagatc 2220 actgacggtg gggtaaaggt gctaagcgaa gagctgacca aatacaaaat tgtgacctat 2280 ttgggtttat acaacaacca gatcaccgat gtcggagcca ggtacgtcac caaaatcctg 2340 gatgaatgca aaggcctcac gcatcttaaa ctgggaaaaa acaaaataac aagtgaagga 2400 gggaagtatc tcgccctggc tgtgaagaac agcaaatcaa tctctgaggt tgggatgtgg 2460 ggcaatcaag ttggggatga aggagcaaaa gccttcgcag aggctctgcg gaaccacccc 2520 agcttgacca ccctgagtct tgcgtccaac ggcatctcca cagaaggagg aaagagcctt 2580 gcgagggccc tgcagcagaa cacgtctcta gaaatactgt ggctgaccca aaatgaactc 2640 aacgatgaag tggcagagag tttggcagaa atgttgaaag tcaaccagac gttaaagcat 2700 ttatggctta tccagaatca gatcacagct aaggggactg cccagctggc agatgcgtta 2760 cagagcaaca ctggcataac agagatttgc ctaaatggaa acctgataaa accagaggag 2820 gccaaagtct atgaagatga gaagcggatt atctgtttc 2859 10 100 PRT Homo sapiens 10 Glu Ser His Pro His Ile Gln Leu Leu Lys Ser Asn Arg Glu Leu Leu 1 5 10 15 Val Thr His Ile Arg Asn Thr Gln Cys Leu Val Asp Asn Leu Leu Lys 20 25 30 Asn Asp Tyr Phe Ser Ala Glu Asp Ala Glu Ile Val Cys Ala Cys Pro 35 40 45 Thr Gln Pro Asp Lys Val Arg Lys Ile Leu Asp Leu Val Gln Ser Lys 50 55 60 Gly Glu Glu Val Ser Glu Phe Phe Leu Tyr Leu Leu Gln Gln Leu Ala 65 70 75 80 Asp Ala Tyr Val Asp Leu Arg Pro Trp Leu Leu Glu Ile Gly Phe Ser 85 90 95 Pro Ser Leu Leu 100 11 200 PRT Homo sapiens 11 Ile Phe Ile Leu Gly Asp Ala Gly Val Gly Lys Ser Met Leu Leu Gln 1 5 10 15 Arg Leu Gln Ser Leu Trp Ala Thr Gly Arg Leu Asp Ala Gly Val Lys 20 25 30 Phe Phe Phe His Phe Arg Cys Arg Met Phe Ser Cys Phe Lys Glu Ser 35 40 45 Asp Arg Leu Cys Leu Gln Asp Leu Leu Phe Lys His Tyr Cys Tyr Pro 50 55 60 Glu Arg Asp Pro Glu Glu Val Phe Ala Phe Leu Leu Arg Phe Pro His 65 70 75 80 Val Ala Leu Phe Thr Phe Asp Gly Leu Asp Glu Leu His Ser Asp Leu 85 90 95 Asp Leu Ser Arg Val Pro Asp Ser Ser Cys Pro Trp Glu Pro Ala His 100 105 110 Pro Leu Val Leu Leu Ala Asn Leu Leu Ser Gly Lys Leu Leu Lys Gly 115 120 125 Ala Ser Lys Leu Leu Thr Ala Arg Thr Gly Ile Glu Val Pro Arg Gln 130 135 140 Phe Leu Arg Lys Lys Val Leu Leu Arg Gly Phe Ser Pro Ser His Leu 145 150 155 160 Arg Ala Tyr Ala Arg Arg Met Phe Pro Glu Arg Ala Leu Gln Asp Arg 165 170 175 Leu Leu Ser Gln Leu Glu Ala Asn Pro Asn Leu Cys Ser Leu Cys Ser 180 185 190 Val Pro Leu Phe Cys Trp Ile Ile 195 200 12 8 PRT Homo sapiens 12 Gly Asp Ala Gly Val Gly Lys Ser 1 5 13 5 PRT Homo sapiens 13 Leu Phe Thr Phe Asp 1 5 14 12 PRT Homo sapiens 14 Ser Lys Leu Leu Thr Ala Arg Thr Gly Ile Glu Val 1 5 10 15 28 PRT Homo sapiens 15 Gly Ile Cys Ala Asn Tyr Leu Lys Leu Thr Tyr Cys Asn Ala Cys Ser 1 5 10 15 Ala Asp Cys Ser Ala Leu Ser Phe Val Leu His His 20 25 16 26 PRT Homo sapiens 16 Phe Pro Lys Arg Leu Ala Leu Asp Leu Asp Asn Asn Asn Leu Asn Asp 1 5 10 15 Tyr Gly Val Arg Glu Leu Gln Pro Cys Phe 20 25 17 27 PRT Homo sapiens 17 Ser Arg Leu Thr Val Leu Arg Leu Ser Val Asn Gln Ile Thr Asp Gly 1 5 10 15 Gly Val Lys Val Leu Ser Glu Glu Leu Thr Lys 20 25 18 28 PRT Homo sapiens 18 Tyr Lys Ile Val Thr Tyr Leu Gly Leu Tyr Asn Asn Gln Ile Thr Asp 1 5 10 15 Val Gly Ala Arg Tyr Val Thr Lys Ile Leu Asp Glu 20 25 19 28 PRT Homo sapiens 19 Cys Lys Gly Leu Thr His Leu Lys Leu Gly Lys Asn Lys Ile Thr Ser 1 5 10 15 Glu Gly Gly Lys Tyr Leu Ala Leu Ala Val Lys Asn 20 25 20 28 PRT Homo sapiens 20 Ser Lys Ser Ile Ser Glu Val Gly Met Trp Gly Asn Gln Val Gly Asp 1 5 10 15 Glu Gly Ala Lys Ala Phe Ala Glu Ala Leu Arg Asn 20 25 21 28 PRT Homo sapiens 21 His Pro Ser Leu Thr Thr Leu Ser Leu Ala Ser Asn Gly Ile Ser Thr 1 5 10 15 Glu Gly Gly Lys Ser Leu Ala Arg Ala Leu Gln Gln 20 25 22 28 PRT Homo sapiens 22 Asn Thr Ser Leu Glu Ile Leu Trp Leu Thr Gln Asn Glu Leu Asn Asp 1 5 10 15 Glu Val Ala Glu Ser Leu Ala Glu Met Leu Lys Val 20 25 23 28 PRT Homo sapiens 23 Asn Gln Thr Leu Lys His Leu Trp Leu Ile Gln Asn Gln Ile Thr Ala 1 5 10 15 Lys Gly Thr Ala Gln Leu Ala Asp Ala Leu Gln Ser 20 25 24 28 PRT Homo sapiens 24 Asn Thr Gly Ile Thr Glu Ile Cys Leu Asn Gly Asn Leu Ile Lys Pro 1 5 10 15 Glu Glu Ala Lys Val Tyr Glu Asp Glu Lys Arg Ile 20 25 25 3080 DNA Homo sapiens CDS (1)...(1470) 25 cac gcg tcc gac ttg ctg aag aat gac tac ttc tcg gcc gaa gat gcg 48 His Ala Ser Asp Leu Leu Lys Asn Asp Tyr Phe Ser Ala Glu Asp Ala 1 5 10 15 gag att gtg tgt gcc tgc ccc acc cag cct gac aag gtc cgc aaa att 96 Glu Ile Val Cys Ala Cys Pro Thr Gln Pro Asp Lys Val Arg Lys Ile 20 25 30 ctg gac ctg gta cag agc aag ggc gag gag gtg tcc gag ttc ttc ctc 144 Leu Asp Leu Val Gln Ser Lys Gly Glu Glu Val Ser Glu Phe Phe Leu 35 40 45 tac ttg ctc cag caa ctc gca gat gcc tac gtg gac ctc agg cct tgg 192 Tyr Leu Leu Gln Gln Leu Ala Asp Ala Tyr Val Asp Leu Arg Pro Trp 50 55 60 ctg ctg gag atc ggc ttc tcc cct tcc ctg ctc act cag agc aaa gtc 240 Leu Leu Glu Ile Gly Phe Ser Pro Ser Leu Leu Thr Gln Ser Lys Val 65 70 75 80 gtg gtc aac act gac cca gtg agc agg tat acc cag cag ctg cga cac 288 Val Val Asn Thr Asp Pro Val Ser Arg Tyr Thr Gln Gln Leu Arg His 85 90 95 cat ctg ggc cgt gac tcc aag ttc gtg ctg tgc tat gcc cag aag gag 336 His Leu Gly Arg Asp Ser Lys Phe Val Leu Cys Tyr Ala Gln Lys Glu 100 105 110 gag ctg ctg ctg gag gag atc tac atg gac acc atc atg gag ctg gtt 384 Glu Leu Leu Leu Glu Glu Ile Tyr Met Asp Thr Ile Met Glu Leu Val 115 120 125 ggc ttc agc aat gag agc ctg ggc agc ctg aac agc ctg gcc tgc ctc 432 Gly Phe Ser Asn Glu Ser Leu Gly Ser Leu Asn Ser Leu Ala Cys Leu 130 135 140 ctg gac cac acc acc ggc atc ctc aat gag cag ggt gag acc atc ttc 480 Leu Asp His Thr Thr Gly Ile Leu Asn Glu Gln Gly Glu Thr Ile Phe 145 150 155 160 atc ctg ggt gat gct ggg gtg ggc aag tcc atg ctg cta cag cgg ctg 528 Ile Leu Gly Asp Ala Gly Val Gly Lys Ser Met Leu Leu Gln Arg Leu 165 170 175 cag agc ctc tgg gcc acg ggc cgg cta gac gca ggg gtc aaa ttc ttc 576 Gln Ser Leu Trp Ala Thr Gly Arg Leu Asp Ala Gly Val Lys Phe Phe 180 185 190 ttc cac ttt cgc tgc cgc atg ttc agc tgc ttc aag gaa agt gac agg 624 Phe His Phe Arg Cys Arg Met Phe Ser Cys Phe Lys Glu Ser Asp Arg 195 200 205 ctg tgt ctg cag gac ctg ctc ttc aag cac tac tgc tac cca gag cgg 672 Leu Cys Leu Gln Asp Leu Leu Phe Lys His Tyr Cys Tyr Pro Glu Arg 210 215 220 gac ccc gag gag gtg ttt gcc ttc ctg ctg cgc ttc ccc cac gtg gcc 720 Asp Pro Glu Glu Val Phe Ala Phe Leu Leu Arg Phe Pro His Val Ala 225 230 235 240 ctc ttc acc ttc gat ggc ctg gac gag ctg cac tcg gac ttg gac ctg 768 Leu Phe Thr Phe Asp Gly Leu Asp Glu Leu His Ser Asp Leu Asp Leu 245 250 255 agc cgc gtg cct gac agc tcc tgc ccc tgg gag cct gcc cac ccc ctg 816 Ser Arg Val Pro Asp Ser Ser Cys Pro Trp Glu Pro Ala His Pro Leu 260 265 270 gtc ttg ctg gcc aac ctg ctc agt ggg aag ctg ctc aag ggg gct agc 864 Val Leu Leu Ala Asn Leu Leu Ser Gly Lys Leu Leu Lys Gly Ala Ser 275 280 285 aag ctg ctc aca gcc cgc aca ggc atc gag gtc ccg cgc cag ttc ctg 912 Lys Leu Leu Thr Ala Arg Thr Gly Ile Glu Val Pro Arg Gln Phe Leu 290 295 300 cgg aag aag gtg ctt ctc cgg ggc ttc tcc ccc agc cac ctg cgc gcc 960 Arg Lys Lys Val Leu Leu Arg Gly Phe Ser Pro Ser His Leu Arg Ala 305 310 315 320 tat gcc agg agg atg ttc ccc gag cgg gcc ctg cag gac cgc ctg ctg 1008 Tyr Ala Arg Arg Met Phe Pro Glu Arg Ala Leu Gln Asp Arg Leu Leu 325 330 335 agc cag ctg gag gcc aac ccc aac ctc tgc agc ctg tgc tct gtg ccc 1056 Ser Gln Leu Glu Ala Asn Pro Asn Leu Cys Ser Leu Cys Ser Val Pro 340 345 350 ctc ttc tgc tgg atc atc ttc cgg tgc ttc cag cac ttc cgt gct gcc 1104 Leu Phe Cys Trp Ile Ile Phe Arg Cys Phe Gln His Phe Arg Ala Ala 355 360 365 ttt gaa ggc tca cca cag ctg ccc gac tgc acg atg acc ctg aca gat 1152 Phe Glu Gly Ser Pro Gln Leu Pro Asp Cys Thr Met Thr Leu Thr Asp 370 375 380 gtc ttc ctc ctg gtc act gag gtc cat ctg aac agg atg cag ccc agc 1200 Val Phe Leu Leu Val Thr Glu Val His Leu Asn Arg Met Gln Pro Ser 385 390 395 400 agc ctg gtg cag cgg aac aca cgc agc cca gtg gag acc ctc cac gcc 1248 Ser Leu Val Gln Arg Asn Thr Arg Ser Pro Val Glu Thr Leu His Ala 405 410 415 ggc cgg gac act ctg tgc tcg ctg ggg cag gtg gcc cac cgg ggc atg 1296 Gly Arg Asp Thr Leu Cys Ser Leu Gly Gln Val Ala His Arg Gly Met 420 425 430 gag aag agc ctc ttt gtc ttc acc cag gag gag gtg cag gcc tcc ggg 1344 Glu Lys Ser Leu Phe Val Phe Thr Gln Glu Glu Val Gln Ala Ser Gly 435 440 445 ctg cag gag aga gac atg cag ctg ggc ttc ctg cgg gct ttg ccg gag 1392 Leu Gln Glu Arg Asp Met Gln Leu Gly Phe Leu Arg Ala Leu Pro Glu 450 455 460 ctg ggc ccc ggg ggt gac cag cag tcc tat gag ttt ttc cac ctc agc 1440 Leu Gly Pro Gly Gly Asp Gln Gln Ser Tyr Glu Phe Phe His Leu Ser 465 470 475 480 ctc ctc acc tgt aaa act ggg atc cca gta tagactttgg aaatcagtag 1490 Leu Leu Thr Cys Lys Thr Gly Ile Pro Val 485 490 acaccatatg cttcaaaaaa caggggctat taaaatgaca tcaggagcca gaaagtctca 1550 tggctgtgct ttctcttgaa gtttatacaa caaccagatc accgatgtcg gagccagact 1610 gggaaaaaac aaaataacaa gtgaaggagg gaagtatctc gccctggctg tgaagaacag 1670 caaatcaatc tctgaggttg ggatgtgggg caatcaagtt ggggatgaag gagcaaaagc 1730 cttcgcagag gctctgcgga accaccccag cttgaccacc ctgagtcttg cgtccaacgg 1790 catctccaca gaaggaggaa agagccttgc gagggccctg cagcagaaca cgtctctaga 1850 aatactgtgg ctgacccaaa atgaactcaa cgatgaagtg gcagagagtt tggcagaaat 1910 gttgaaagtc aaccagacgt taaagcattt atggcttatc cagaatcaga tcacagtctt 1970 ttgtgtcagt gtcttaaagg ggcctgcgca ggcgggacta tcaggagtcc actgcctcca 2030 tgatgcaagc cagcttcctg tgcagaaggt ctggtcggca aactccctaa gtacccgcta 2090 caattctgca gaaaaagaat gtgtcttgcg agctgttgta gttacagtaa atacactgtg 2150 aagagacttt attgcctatt ataattattt ttatctgaag ctagaggaat aaagctgtga 2210 gcaaacagag gaggccagcc tcacctcatt ccaacacctg ccatagggac caacgggagc 2270 gagttggtca ccgctctttt cattgaagag ttgaggatgt ggcacaaagt tggtgccaag 2330 cttcttgaat aaaacgtgtt tgatggatta gtattatacc tgaaatattt tcttccttct 2390 cagcactttc ccatgtattg atactggtcc cacttcacag ctggagacac cggagtatgt 2450 gcagtgtggg atttgactcc tccaaggttt tgtggaaagt taatgtcaag gaaaggatgc 2510 accacgggct tttaatttta atcctggagt ctcactgtct gctggcaaag atagagaatg 2570 ccctcagctc ttagctggtc taagaatgac gatgccttca aaatgctgct tccactcagg 2630 gcttctcctc tgctaggcta ccctcctcta gaaggctgag taccatgggc tacagtgtct 2690 ggccttggga agaagtgatt ctgtccctcc aaagaaatag ggcatggctt gcccctgtgg 2750 ccctggcatc caaatggctg cttttgtctc ccttacctcg tgaagagggg aagtctcttc 2810 ctgcctccca agcagctgaa gggtgactaa acgggcgcca agactcaggg gatcggctgg 2870 gaactgggcc agcagagcat gttggacacc ccccaccatg gtgggcttgt ggtggctgct 2930 ccatgagggt gggggtgata ctactagatc acttgtcctc ttgccagctc atttgttaat 2990 aaaatactga aaacacaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3050 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3080 26 490 PRT Homo sapiens 26 His Ala Ser Asp Leu Leu Lys Asn Asp Tyr Phe Ser Ala Glu Asp Ala 1 5 10 15 Glu Ile Val Cys Ala Cys Pro Thr Gln Pro Asp Lys Val Arg Lys Ile 20 25 30 Leu Asp Leu Val Gln Ser Lys Gly Glu Glu Val Ser Glu Phe Phe Leu 35 40 45 Tyr Leu Leu Gln Gln Leu Ala Asp Ala Tyr Val Asp Leu Arg Pro Trp 50 55 60 Leu Leu Glu Ile Gly Phe Ser Pro Ser Leu Leu Thr Gln Ser Lys Val 65 70 75 80 Val Val Asn Thr Asp Pro Val Ser Arg Tyr Thr Gln Gln Leu Arg His 85 90 95 His Leu Gly Arg Asp Ser Lys Phe Val Leu Cys Tyr Ala Gln Lys Glu 100 105 110 Glu Leu Leu Leu Glu Glu Ile Tyr Met Asp Thr Ile Met Glu Leu Val 115 120 125 Gly Phe Ser Asn Glu Ser Leu Gly Ser Leu Asn Ser Leu Ala Cys Leu 130 135 140 Leu Asp His Thr Thr Gly Ile Leu Asn Glu Gln Gly Glu Thr Ile Phe 145 150 155 160 Ile Leu Gly Asp Ala Gly Val Gly Lys Ser Met Leu Leu Gln Arg Leu 165 170 175 Gln Ser Leu Trp Ala Thr Gly Arg Leu Asp Ala Gly Val Lys Phe Phe 180 185 190 Phe His Phe Arg Cys Arg Met Phe Ser Cys Phe Lys Glu Ser Asp Arg 195 200 205 Leu Cys Leu Gln Asp Leu Leu Phe Lys His Tyr Cys Tyr Pro Glu Arg 210 215 220 Asp Pro Glu Glu Val Phe Ala Phe Leu Leu Arg Phe Pro His Val Ala 225 230 235 240 Leu Phe Thr Phe Asp Gly Leu Asp Glu Leu His Ser Asp Leu Asp Leu 245 250 255 Ser Arg Val Pro Asp Ser Ser Cys Pro Trp Glu Pro Ala His Pro Leu 260 265 270 Val Leu Leu Ala Asn Leu Leu Ser Gly Lys Leu Leu Lys Gly Ala Ser 275 280 285 Lys Leu Leu Thr Ala Arg Thr Gly Ile Glu Val Pro Arg Gln Phe Leu 290 295 300 Arg Lys Lys Val Leu Leu Arg Gly Phe Ser Pro Ser His Leu Arg Ala 305 310 315 320 Tyr Ala Arg Arg Met Phe Pro Glu Arg Ala Leu Gln Asp Arg Leu Leu 325 330 335 Ser Gln Leu Glu Ala Asn Pro Asn Leu Cys Ser Leu Cys Ser Val Pro 340 345 350 Leu Phe Cys Trp Ile Ile Phe Arg Cys Phe Gln His Phe Arg Ala Ala 355 360 365 Phe Glu Gly Ser Pro Gln Leu Pro Asp Cys Thr Met Thr Leu Thr Asp 370 375 380 Val Phe Leu Leu Val Thr Glu Val His Leu Asn Arg Met Gln Pro Ser 385 390 395 400 Ser Leu Val Gln Arg Asn Thr Arg Ser Pro Val Glu Thr Leu His Ala 405 410 415 Gly Arg Asp Thr Leu Cys Ser Leu Gly Gln Val Ala His Arg Gly Met 420 425 430 Glu Lys Ser Leu Phe Val Phe Thr Gln Glu Glu Val Gln Ala Ser Gly 435 440 445 Leu Gln Glu Arg Asp Met Gln Leu Gly Phe Leu Arg Ala Leu Pro Glu 450 455 460 Leu Gly Pro Gly Gly Asp Gln Gln Ser Tyr Glu Phe Phe His Leu Ser 465 470 475 480 Leu Leu Thr Cys Lys Thr Gly Ile Pro Val 485 490 27 1470 DNA Homo sapiens 27 cacgcgtccg acttgctgaa gaatgactac ttctcggccg aagatgcgga gattgtgtgt 60 gcctgcccca cccagcctga caaggtccgc aaaattctgg acctggtaca gagcaagggc 120 gaggaggtgt ccgagttctt cctctacttg ctccagcaac tcgcagatgc ctacgtggac 180 ctcaggcctt ggctgctgga gatcggcttc tccccttccc tgctcactca gagcaaagtc 240 gtggtcaaca ctgacccagt gagcaggtat acccagcagc tgcgacacca tctgggccgt 300 gactccaagt tcgtgctgtg ctatgcccag aaggaggagc tgctgctgga ggagatctac 360 atggacacca tcatggagct ggttggcttc agcaatgaga gcctgggcag cctgaacagc 420 ctggcctgcc tcctggacca caccaccggc atcctcaatg agcagggtga gaccatcttc 480 atcctgggtg atgctggggt gggcaagtcc atgctgctac agcggctgca gagcctctgg 540 gccacgggcc ggctagacgc aggggtcaaa ttcttcttcc actttcgctg ccgcatgttc 600 agctgcttca aggaaagtga caggctgtgt ctgcaggacc tgctcttcaa gcactactgc 660 tacccagagc gggaccccga ggaggtgttt gccttcctgc tgcgcttccc ccacgtggcc 720 ctcttcacct tcgatggcct ggacgagctg cactcggact tggacctgag ccgcgtgcct 780 gacagctcct gcccctggga gcctgcccac cccctggtct tgctggccaa cctgctcagt 840 gggaagctgc tcaagggggc tagcaagctg ctcacagccc gcacaggcat cgaggtcccg 900 cgccagttcc tgcggaagaa ggtgcttctc cggggcttct cccccagcca cctgcgcgcc 960 tatgccagga ggatgttccc cgagcgggcc ctgcaggacc gcctgctgag ccagctggag 1020 gccaacccca acctctgcag cctgtgctct gtgcccctct tctgctggat catcttccgg 1080 tgcttccagc acttccgtgc tgcctttgaa ggctcaccac agctgcccga ctgcacgatg 1140 accctgacag atgtcttcct cctggtcact gaggtccatc tgaacaggat gcagcccagc 1200 agcctggtgc agcggaacac acgcagccca gtggagaccc tccacgccgg ccgggacact 1260 ctgtgctcgc tggggcaggt ggcccaccgg ggcatggaga agagcctctt tgtcttcacc 1320 caggaggagg tgcaggcctc cgggctgcag gagagagaca tgcagctggg cttcctgcgg 1380 gctttgccgg agctgggccc cgggggtgac cagcagtcct atgagttttt ccacctcagc 1440 ctcctcacct gtaaaactgg gatcccagta 1470 28 74 PRT Homo sapiens 28 His Ala Ser Asp Leu Leu Lys Asn Asp Tyr Phe Ser Ala Glu Asp Ala 1 5 10 15 Glu Ile Val Cys Ala Cys Pro Thr Gln Pro Asp Lys Val Arg Lys Ile 20 25 30 Leu Asp Leu Val Gln Ser Lys Gly Glu Glu Val Ser Glu Phe Phe Leu 35 40 45 Tyr Leu Leu Gln Gln Leu Ala Asp Ala Tyr Val Asp Leu Arg Pro Trp 50 55 60 Leu Leu Glu Ile Gly Phe Ser Pro Ser Leu 65 70 29 8 PRT Homo sapiens 29 Gly Asp Ala Gly Val Gly Lys Ser 1 5 30 5 PRT Homo sapiens 30 Leu Phe Thr Phe Asp 1 5 31 94 PRT Homo sapiens 31 Ala Gln Glu Arg Pro Ser Glu Thr Thr Asp Arg Glu Arg Lys Arg Leu 1 5 10 15 Val Glu Thr Leu Gln Ala Asp Ser Gly Leu Leu Leu Asp Ala Leu Leu 20 25 30 Ala Arg Gly Val Leu Thr Gly Pro Glu Tyr Glu Ala Leu Asp Ala Leu 35 40 45 Pro Asp Ala Glu Arg Arg Val Arg Arg Leu Leu Leu Leu Val Gln Gly 50 55 60 Lys Gly Glu Ala Ala Cys Gln Glu Leu Leu Arg Cys Ala Gln Arg Thr 65 70 75 80 Ala Gly Ala Pro Asp Pro Ala Trp Asp Trp Gln His Val Gly 85 90 32 89 PRT Homo sapiens 32 Met Ala Ser Asp Asp Leu Ser Leu Ile Arg Lys Asn Arg Met Ala Leu 1 5 10 15 Phe Gln Gln Leu Thr Cys Val Leu Pro Ile Leu Asp Asn Leu Leu Lys 20 25 30 Ala Asn Val Thr Asn Lys Gln Glu His Asp Ile Ile Lys Gln Lys Thr 35 40 45 Gln Ile Pro Leu Gln Ala Arg Glu Leu Ile Asp Thr Ile Trp Val Lys 50 55 60 Gly Asn Ala Ala Ala Asn Ile Phe Lys Asn Cys Leu Lys Glu Ile Asp 65 70 75 80 Ser Thr Leu Tyr Lys Asn Leu Phe Val 85 33 89 PRT Homo sapiens 33 Lys Glu Ser Asn Asp Leu Leu Leu Ile Arg Lys Asn Arg Met Ala Leu 1 5 10 15 Phe Gln His Leu Thr Cys Val Ile Pro Ile Leu Asp Ser Leu Leu Thr 20 25 30 Ala Gly Ile Ile Asn Glu Gln Glu His Asp Val Ile Lys Gln Lys Thr 35 40 45 Gln Thr Ser Leu Gln Ala Arg Glu Leu Ile Asp Thr Ile Leu Val Lys 50 55 60 Gly Asn Ile Ala Ala Thr Val Phe Arg Asn Ser Leu Gln Glu Ala Glu 65 70 75 80 Ala Val Leu Tyr Glu His Leu Phe Val 85 34 24 DNA Homo sapiens 34 ccctggtact tgcccctccg gtag 24 35 18 DNA Homo sapiens 35 cctggtactt gcccctcc 18 36 23 DNA Homo sapiens 36 tcgttaagcc cttgaagaca gtg 23 37 30 DNA Homo sapiens 37 tcgttagccc ttgaagacca gtgagtgtag 30 

What is claimed is:
 1. An isolated nucleic acid molecule selected from the group consisting of: a) a nucleic acid molecule comprising a nucleotide sequence which is at least 55% identical to the nucleotide sequence of SEQ ID NO:7 or SEQ ID NO:9, the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, or a complement thereof; b) a nucleic acid molecule comprising-a nucleotide sequence which is at least 55% identical to the nucleotide sequence of SEQ ID NO:25 or SEQ ID NO:27, the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, or a complement thereof; c) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:7 or SEQ ID NO:9, the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, or a complement thereof; d) a nucleic acid molecule comprising a fragment of at least 300 nucleotides of the nucleotide sequence of SEQ ID NO:25 or SEQ ID NO:27, the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, or a complement thereof; e) nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______; f) nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______; g) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8 or the polypeptide encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______; and h) a nucleic acid molecule which encodes a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:26, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:26 or the polypeptide encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______; and i) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 or SEQ ID NO:9 under stringent conditions. j) a nucleic acid molecule which encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:25 or SEQ ID NO:27 under stringent conditions.
 2. The isolated nucleic acid molecule of claim 1, which is selected from the group consisting of: a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:7 or SEQ ID NO:9, or the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, or a complement thereof; and b) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:25 or SEQ ID NO:27, or the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, or a complement thereof; and c) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______. d) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______.
 3. The nucleic acid molecule of claim 1 further comprising vector nucleic acid sequences.
 4. The nucleic acid molecule of claim 1 further comprising nucleic acid sequences encoding a heterologous polypeptide.
 5. A host cell which contains the nucleic acid molecule of claim
 1. 6. The host cell of claim 4 which is a mammalian host cell.
 7. A non-human mammalian host cell containing the nucleic acid molecule of claim
 1. 8. An isolated polypeptide selected from the group consisting of: a) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:8, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8. b) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:26, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:26. c) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 or SEQ ID NO:9 under stringent conditions; d) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:25 or SEQ ID NO:27 under stringent conditions; e) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 55% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:7 or SEQ ID NO:9. f) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 55% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:25 or SEQ ID NO:27.
 9. The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number______.
 10. The polypeptide of claim 8 further comprising heterologous amino acid sequences.
 11. An antibody which selectively binds to a polypeptide of claim
 8. 12. A method for producing a polypeptide selected from the group consisting of: a) a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______; b) a polypeptide comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______; c) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______; d) a fragment of a polypeptide comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the fragment comprises at least 15 contiguous amino acids of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______; e) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:8 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:7 or SEQ ID NO:9 under stringent conditions; f) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule comprising SEQ ID NO:25 or SEQ ID NO:27 under stringent conditions; comprising culturing the host cell of claim 5 under conditions in which the nucleic acid molecule is expressed.
 13. The isolated polypeptide of claim 8 comprising the amino acid sequence of SEQ ID NO:8 or SEQ ID NO:26 or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Accession Number ______.
 14. A method for detecting the presence of a polypeptide of claim 8 in a sample, comprising: a) contacting the sample with a compound which selectively binds to a polypeptide of claim 8; and b) determining whether the compound binds to the polypeptide of claim 8 in the sample.
 15. The method of claim 14, wherein the compound which binds to the polypeptide is an antibody.
 16. A kit comprising a compound which selectively binds to a polypeptide of claim 8 and instructions for use.
 17. A method for detecting the presence of a nucleic acid molecule of claim 1 in a sample, comprising the steps of: a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
 18. The method of claim 17, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.
 19. A kit comprising a compound which selectively hybridizes to a nucleic acid molecule of claim 1 and instructions for use.
 20. A method for identifying a compound which binds to a polypeptide of claim 8 comprising the steps of: a) contacting a polypeptide, or a cell expressing a polypeptide of claim 8 with a test compound; and b) determining whether the polypeptide binds to the test compound.
 21. The method of claim 20, wherein the binding of the test compound to the polypeptide is detected by a method selected from the group consisting of: a) detection of binding by direct detecting of test compound/polypeptide binding; b) detection of binding using a competition binding assay; c) detection of binding using an assay for CARD-4L or CARD-4S mediated signal transduction.
 22. A method for modulating the activity of a polypeptide of claim 8 comprising contacting a polypeptide or a cell expressing a polypeptide of claim 8 with a compound which binds to the polypeptide in a sufficient concentration to modulate the activity of the polypeptide.
 23. A method for identifying a compound which modulates the activity of a polypeptide of claim 8, comprising: a) contacting a polypeptide of claim 8 with a test compound; and b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide. 